<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54100</article-id><article-id pub-id-type="doi">10.7554/eLife.54100</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>Evolution of multifunctionality through a pleiotropic substitution in the innate immune protein S100A9</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-167118"><name><surname>Harman</surname><given-names>Joseph L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8283-0301</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167119"><name><surname>Loes</surname><given-names>Andrea N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167120"><name><surname>Warren</surname><given-names>Gus D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167121"><name><surname>Heaphy</surname><given-names>Maureen C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167122"><name><surname>Lampi</surname><given-names>Kirsten J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-37361"><name><surname>Harms</surname><given-names>Michael J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0241-4122</contrib-id><email>harms@uoregon.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Chemistry and Biochemistry, University of Oregon</institution><addr-line><named-content content-type="city">Eugene</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Institute of Molecular Biology, University of Oregon</institution><addr-line><named-content content-type="city">Eugene</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Oregon Health &amp; Science University</institution><addr-line><named-content content-type="city">Portland</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard TH Chan School of Public Health</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Laub</surname><given-names>Michael T</given-names></name><role>Reviewing Editor</role><aff><institution>Massachusetts Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>04</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e54100</elocation-id><history><date date-type="received" iso-8601-date="2019-12-02"><day>02</day><month>12</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-04-03"><day>03</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Harman et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Harman et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54100-v2.pdf"/><abstract><p>Multifunctional proteins are evolutionary puzzles: how do proteins evolve to satisfy multiple functional constraints? S100A9 is one such multifunctional protein. It potently amplifies inflammation via Toll-like receptor four and is antimicrobial as part of a heterocomplex with S100A8. These two functions are seemingly regulated by proteolysis: S100A9 is readily degraded, while S100A8/S100A9 is resistant. We take an evolutionary biochemical approach to show that S100A9 evolved both functions and lost proteolytic resistance from a weakly proinflammatory, proteolytically resistant amniote ancestor. We identify a historical substitution that has pleiotropic effects on S100A9 proinflammatory activity and proteolytic resistance but has little effect on S100A8/S100A9 antimicrobial activity. We thus propose that mammals evolved S100A8/S100A9 antimicrobial and S100A9 proinflammatory activities concomitantly with a proteolytic ‘timer’ to selectively regulate S100A9. This highlights how the same mutation can have pleiotropic effects on one functional state of a protein but not another, thus facilitating the evolution of multifunctionality.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>A single protein sometimes does multiple jobs. For instance, our immune system uses a small number of multipurpose proteins to respond quickly to a large number of threats. One example is the protein S100A9. It acts as an antimicrobial by preventing microbes from getting the nutrients they need, while also stimulating inflammation by inducing the release of molecules that recruit white blood cells.</p><p>S100A9, like all proteins, is made up of a chain of small building blocks. These building blocks interact with each other and with other molecules in the environment. The sequence of the building blocks thus determines what jobs the protein can do. Therefore, a single change to the sequence of building blocks can have a dramatic effect: one change might render the protein faulty, while another change might allow it to do a new job.</p><p>Proteins face similar challenges humans do when trying to do several things at once. A person driving a car while using their phone will not do either task well. Likewise, a protein that does two jobs faces challenges a single-purpose protein does not.</p><p>Harman et al. were interested in how S100A9 was able to evolve and maintain its dual functionality, despite this potential problem. They started by asking when S100A9 acquired its two purposes. They measured the antimicrobial and inflammatory activity of S100A9 proteins from humans, mice and opossums. The activities of S100A9 in these species was similar, suggesting that S100A9 acquired its different jobs in the ancestor of mammals, some 160 million years ago.</p><p>Next, Harman et al. computationally reconstructed ancestral forms of S100A9 by comparing hundreds of similar proteins and building an evolutionary tree. They then measured the antimicrobial and inflammatory activity of these ancestral proteins. By comparing the last ancestor that did not have these activities to the first ancestor that did, they identified the sequence changes that gave S100A9 its dual activity. Importantly, these changes are located in separate regions of the protein, meaning they could occur independently, without affecting each other. Further, the same sequence change that converted S100A9 into an inflammatory signal also introduced a mechanism to regulate this activity.</p><p>The results suggest that a small number of sequence changes – or even a single change – can make a protein more versatile. This means that evolving multipurpose proteins may not be as difficult as is often thought.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>protein evolution</kwd><kwd>pleiotropy</kwd><kwd>ancestral sequence reconstruction</kwd><kwd>inflammation</kwd><kwd>antimicrobial activity</kwd><kwd>mammals</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>16 15BGIA22830013</award-id><principal-award-recipient><name><surname>Harms</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000875</institution-id><institution>Pew Charitable Trusts</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Harms</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>3R01GM117140-03S1</award-id><principal-award-recipient><name><surname>Harms</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM007413</award-id><principal-award-recipient><name><surname>Harman</surname><given-names>Joseph L</given-names></name><name><surname>Loes</surname><given-names>Andrea N</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In the ancestor of mammals, a multifunctional innate immune protein evolved when a mutation enhanced the protein’s pro-inflammatory activity and proteolytic regulation without disrupting the protein’s antimicrobial activity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The innate immune system uses a small number of multifunctional proteins to respond to diverse immune challenges (<xref ref-type="bibr" rid="bib59">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Auvynet and Rosenstein, 2009</xref>; <xref ref-type="bibr" rid="bib75">Postel et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Gudmundsson and Agerberth, 1999</xref>). Multifunctional immune proteins are critical for pathogen defense, (<xref ref-type="bibr" rid="bib2">Auvynet and Rosenstein, 2009</xref>; <xref ref-type="bibr" rid="bib75">Postel et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Gudmundsson and Agerberth, 1999</xref>) shaping host-associated microbial communities, (<xref ref-type="bibr" rid="bib84">Singh et al., 2016</xref>) and well-regulated tissue growth (<xref ref-type="bibr" rid="bib79">Säemann et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Bals and Wilson, 2003</xref>; <xref ref-type="bibr" rid="bib57">Leask and Abraham, 2003</xref>). They also drive pathological inflammation in disease, including autoimmune disorders, cancer, and cardiovascular disease (<xref ref-type="bibr" rid="bib21">Ehrchen et al., 2009</xref>; <xref ref-type="bibr" rid="bib80">Salama et al., 2008</xref>; <xref ref-type="bibr" rid="bib82">Shabani et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Gruden et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Peng et al., 2018</xref>). These multifunctional proteins raise both mechanistic and evolutionary questions. How can one protein sequence satisfy the multiple constraints imposed by having multiple functions? How can multiple functions evolve in one protein when, as a result of multifunctionality, each mutation likely has pleiotropic effects? (<xref ref-type="bibr" rid="bib59">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Bomblies and Doebley, 2006</xref>; <xref ref-type="bibr" rid="bib86">Stearns, 2010</xref>; <xref ref-type="bibr" rid="bib70">Paaby and Rockman, 2013</xref>).</p><p>One such multifunctional protein is S100A9 (A9), a small, soluble protein found at high concentrations in the extracellular space during an inflammatory response (<xref ref-type="bibr" rid="bib6">Berntzen and Fagerhol, 1990</xref>). It has at least two key immune functions. As a homodimer, A9 potently activates inflammation via Toll-like receptor 4 (TLR4) (<xref ref-type="bibr" rid="bib91">Vogl et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Källberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Duan et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Shepherd et al., 2006</xref>; <xref ref-type="bibr" rid="bib81">Schiopu and Cotoi, 2013</xref>; <xref ref-type="bibr" rid="bib56">Laouedj et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Gao et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Tsai et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Björk et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Kang et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Stríz and Trebichavský, 2004</xref>). As a heterocomplex with S100A8 (A8/A9, also known as calprotectin), it is antimicrobial (<xref ref-type="fig" rid="fig1">Figure 1a</xref>; <xref ref-type="bibr" rid="bib7">Besold et al., 2018a</xref>; <xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Damo et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Clark et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Besold et al., 2018b</xref>; <xref ref-type="bibr" rid="bib65">Nakashige et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Hayden et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Nakashige et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Baker et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Gagnon et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Nisapakultorn et al., 2001</xref>). A9 exacerbates endotoxin-induced shock in mice (<xref ref-type="bibr" rid="bib90">Vogl et al., 2007</xref>). Both A9 and A8/A9 are primary biomarkers for many human inflammatory diseases (<xref ref-type="bibr" rid="bib92">Vogl et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Hara et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Obry et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Horvath et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2015</xref>). Further, dysregulation of A9 is associated with various cancers, pulmonary disorders, and Alzheimer’s disease (<xref ref-type="bibr" rid="bib52">Källberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib92">Vogl et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Hara et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Obry et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Horvath et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Kim et al., 2009</xref>; <xref ref-type="bibr" rid="bib3">Averill et al., 2012</xref>). Understanding the mechanisms by which A9 performs its innate immune functions is critical for developing treatments for A9-mediated diseases.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>A9s evolved to form the antimicrobial A8/A9 complex early in mammals.</title><p>(<bold>a</bold>) Table of A9 and A8/A9 properties. ‘~” represents weak or ambiguously characterized function, check marks and red ‘X’ represent confirmed property (check) or lack thereof (‘x’). (<bold>b</bold>) Schematic of previously published S100 protein tree. Colored nodes represent single protein sequences. Species cartoons shown are human, opossum, and chicken. Ancestrally reconstructed protein nodes are labeled. Branch lengths not to scale. (<bold>c</bold>) Representative growth curves for <italic>Staphylococcus epidermidis</italic> in the presence or absence of 10 μM S100 proteins. Each point represents optical density at 600 nm. <italic>S. epidermidis</italic> growth alone and in the presence of modern proteins are shown as circles, growth in the presence of ancestrally reconstructed proteins shown as triangles. Error bars are standard deviation of three technical replicates. (<bold>d</bold>) Percent of untreated <italic>S. epidermidis</italic> growth at 12 hr with S100 protein treatments. Data are average of three biological replicates. Error bars are standard error of the mean. Species cartoon labels are the same as in (<bold>b</bold>).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Antimicrobial activity of S100 proteins.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The residues composing the A8/A9 hexastidine site are conserved across mammalian and ancestrally reconstructed A8s and A9s.</title><p>Human (h), mouse (m), opossum (op), maximum likelihood therian mammalian ancestors (anc), and AltAll ancestors (altanc) shown. Alignment truncated to show conservation of key hexahistidine site metal- binding residues (boxed + arrows). A8s conserve two (positions 17 and 27 in human A8), while A9s conserve four (positions 91, 95, 103, and 105 of human A9). Consensus residues for alignment are highlighted.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Analysis of protein oligomeric state using SECMALS.</title><p>Differential refractive index (left y-axis, lines) and calculated molecular weights from light scattering detectors (right y-axis, points) for modern S100 proteins used in this study. h = human, op = opossum, ch = chicken species. Opossum A8 + A9 sample is an equimolar mixture of opossum A8 and A9 homodimers. Table below shows summary data calculated using Wyatt Astra software.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Bacterial growth in the presence of S100 proteins.</title><p>Representative <italic>S. epidermidis</italic> growth curves in the presence of (<bold>a</bold>) human A9, (<bold>b</bold>) human A9 M63F, (<bold>c</bold>) human A8/A9, (<bold>d</bold>) human A8/A9 M63F, (<bold>e</bold>) opossum A8/A9 (cysteine-free), (<bold>f</bold>) opossum A8/A9 (containing cysteines), (<bold>g</bold>) ancA8/A9, and h) altancA8/A9. Error bars are the standard deviation for three technical replicates, points show one representative biological replicate for each protein at four different concentrations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Statistics for ancestrally reconstructed proteins.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Secondary structure characterization of ancestrally reconstructed S100s by CD spectroscopy.</title><p>Data shown are the average of 3 scans. Solid lines are maximum likelihood ancestral proteins, dotted lines are alt-all ancestors (colored the same as matching maximum likelihood ancestor for comparison).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig1-figsupp5-v2.tif"/></fig></fig-group><p>The mechanism of A8/A9 antimicrobial activity is well established: it sequesters a variety of transition metals through both a hexahistidine site and a His<sub>3</sub>Asp site formed at the A8/A9 heterodimer interface, thereby limiting the concentrations of essential microbial nutrients in the extracellular space (<xref ref-type="bibr" rid="bib7">Besold et al., 2018a</xref>; <xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Damo et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Clark et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Besold et al., 2018b</xref>; <xref ref-type="bibr" rid="bib65">Nakashige et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Hayden et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Nakashige et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Baker et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Gagnon et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Nisapakultorn et al., 2001</xref>). Other S100 proteins exert weaker antimicrobial activity via the His<sub>3</sub>Asp site, which has lower metal-binding affinity and binds fewer types of transition metals than the A8/A9 hexahistidine site (<xref ref-type="bibr" rid="bib65">Nakashige et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Hayden et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Nakashige et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">Bozzi and Nolan, 2020</xref>; <xref ref-type="bibr" rid="bib18">Cunden and Nolan, 2018</xref>). In contrast, the proinflammatory mechanism of A9 is not well understood. A9 acts as a Damage-Associated Molecular Pattern (DAMP), activating NF-κB and other cytokines through Toll-like receptor 4 (TLR4) (<xref ref-type="bibr" rid="bib91">Vogl et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Källberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Duan et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Shepherd et al., 2006</xref>; <xref ref-type="bibr" rid="bib81">Schiopu and Cotoi, 2013</xref>; <xref ref-type="bibr" rid="bib56">Laouedj et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Gao et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Tsai et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Björk et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Kang et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2015</xref>). The interaction interface(s), affinity, and stoichiometry for the A9/TLR4 interaction are not known. A small region of A9 has been suggested to form part of the A9/TLR4 binding surface, (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>) but no mutant of A9 has been identified that substantially compromises its activation of TLR4.</p><p>An additional layer of A9 immune function is that A9 and A8/A9 are thought to be regulated in the extracellular milieu by proteases. Neutrophils release multiple proteases along with A9 at sites of inflammation that regulate the inflammatory response (<xref ref-type="bibr" rid="bib40">Henry et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Stapels et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Kessenbrock et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Heutinck et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Janoff, 1972</xref>; <xref ref-type="bibr" rid="bib50">Jerke et al., 2015</xref>). A9 is very susceptible to proteolytic degradation, while A8/A9 is highly resistant (<xref ref-type="fig" rid="fig1">Figure 1a</xref>; <xref ref-type="bibr" rid="bib62">Nacken and Kerkhoff, 2007</xref>; <xref ref-type="bibr" rid="bib77">Riva et al., 2013</xref>). Proteolysis may serve to purge proinflammatory A9 from sites of inflammation and thus selectively enrich for antimicrobial A8/A9. There may even be a direct, functional link between A9 proteolytic degradation and inflammation. Proteolytic fragments of A9 are sufficient to activate TLR4, (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>) and proinflammatory stimuli are thought to stabilize A9 homodimers against proteolytic degradation (<xref ref-type="bibr" rid="bib77">Riva et al., 2013</xref>). Directly testing the relationship between A9 proteolytic susceptibility and proinflammatory activity, however, has been challenging. There is no obvious way to selectively increase the proteolytic resistance of A9 and test its effect on A9 activation of TLR4, making it difficult to understand the relationship, if any, between these two functions.</p><p>We took an evolutionary biochemical approach to mechanistically dissect the evolution of A9 innate immune functions. Using phylogenetics, ancestral sequence reconstruction (ASR), and biochemical studies, we show that A9s evolved to form proteolytically resistant, antimicrobial A8/A9 complexes in early mammals. We find that A9 homodimers gained proinflammatory activity and lost proteolytic resistance in the ancestor of therian mammals from a weakly proinflammatory, proteolytically resistant amniote ancestor. We identify a pleiotropic substitution that is necessary for A9 activation of TLR4, sufficient to increase TLR4 activation by the A9 amniote ancestor and played a role in loss of A9 proteolytic resistance. Mutating this site has minimal effect on A8/A9 antimicrobial activity or proteolytic resistance. Lastly, we show that proteolysis is not required for A9 activation of TLR4. Taken together, this work reveals that mammals concomitantly evolved A8/A9 antimicrobial activity, A9 proinflammatory activity, and a way to selectively regulate A9 inflammation via loss of A9 proteolytic resistance. These findings provide unprecedented mechanistic and evolutionary insight into A9 function and show how a single mutation can have pleiotropic effects in one functional state of a protein while not impacting another, thus facilitating the evolution of multifunctionality.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>We first set out to establish when A9 evolved three innate immune properties: antimicrobial activity via formation of the A8/A9 complex, proinflammatory activation of TLR4 by A9 alone, and the differential proteolytic susceptibility of A9 and A8/A9.</p><sec id="s2-1"><title>A9s evolved to form antimicrobial A8/A9 complexes early in mammals</title><p>We sought to determine when A9 evolved to form the antimicrobial A8/A9 complex. We hypothesized that A8/A9 antimicrobial activity evolved in the ancestor of therian mammals (the shared ancestor of marsupials and placental mammals) for several reasons. First, the broad-spectrum antimicrobial activity of human and mouse A8/A9 is well established (<xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Damo et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Clark et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Besold et al., 2018b</xref>; <xref ref-type="bibr" rid="bib65">Nakashige et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Hayden et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Nakashige et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Baker et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Gagnon et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Nisapakultorn et al., 2001</xref>). Second, A9 and A8 genes are only found together in therian mammals (<xref ref-type="fig" rid="fig1">Figure 1b</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>); therefore the A8/A9 complex could not have arisen earlier than in the ancestor of therian mammals. Lastly, the residues composing the antimicrobial hexahistidine metal-binding site are fully conserved across therian mammals (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>To determine whether the antimicrobial A8/A9 complex arose in the ancestor of therian mammals, we compared human A8/A9 to two previously uncharacterized A8/A9 complexes. We first tested the antimicrobial activity of A8/A9 from opossum, which is one of the earliest-diverging mammals relative to humans that possesses both of the S100A8 and S100A9 genes. Opossum and human A8 and opossum and human A9 have sequence identities of approximately 50%, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Following previous work, (<xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>) we produced a cysteine-free variant of the complex to avoid the use of reducing agents in the antimicrobial assay. We confirmed that cysteine-free opossum A8/A9 formed a heterotetramer (46.8 ± 0.7 kDa) in the presence of calcium – like the human and mouse proteins (<xref ref-type="bibr" rid="bib87">Streicher et al., 2010</xref>) – using size exclusion chromatography coupled with multi-angle laser light scattering (SEC MALS, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>We measured cysteine-free opossum A8/A9 antimicrobial activity against a representative gram-negative bacterium, <italic>Staphylococcus epidermidis</italic>. In studies of A8/A9 from other species, activity against <italic>S. epidermidis</italic> tracked with the broad-spectrum antimicrobial activity of the complex (<xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>). We assayed activity using a previously established in vitro antimicrobial assay that monitors bacterial growth in the absence or presence of S100 proteins (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>; <xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>). To compare the activity of different proteins, we quantified inhibition at seven hours (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). We observed a dose-dependent decrease in <italic>S. epidermidis</italic> growth in the presence of low micromolar concentrations of cysteine-free opossum A8/A9 (<xref ref-type="fig" rid="fig1">Figure 1c–d</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). The antimicrobial activity of opossum A8/A9 was weaker than that of human A8/A9: opossum A8/A9 delayed bacterial growth, while human A8/A9 both delayed growth and decreased bacterial carrying capacity (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). It was previously found that cysteine-free human A8/A9 was potently antimicrobial, (<xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>) while cysteine-free mouse A8/A9 exhibits weaker antimicrobial activity than wildtype mouse A8/A9 (<xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>). To determine whether the weaker activity of opossum A8/A9 was due to the removal of cysteines, we also measured the activity of wildtype opossum A8/A9 against <italic>S. epidermidis</italic>. We found that wildtype opossum A8/A9 had higher activity than cysteine-free opossum A8/A9 over the concentration range tested (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). This suggests that the cysteines present in mouse and opossum A8/A9 play a role in their antimicrobial activity, unlike in human A8/A9. The antimicrobial activity of the opossum A8/A9 complex thus appears to be more similar to that of mouse A8/A9 than human A8/A9.</p><p>The shared antimicrobial activity of human, mouse, and opossum A8/A9 strongly suggests that the antimicrobial A8/A9 complex evolved in the ancestor of therian mammals. To test this further, we measured the antimicrobial activity of ancestrally reconstructed therian mammalian A8/A9 (ancA8/A9 – <xref ref-type="fig" rid="fig1">Figure 1b</xref>). We used our previously published phylogenetic tree (<xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>) consisting of 172 S100 sequences to reconstruct therian mammalian ancestral A8 and A9 (ancA9 and ancA8 – <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary files 1</xref>–<xref ref-type="supplementary-material" rid="supp2">2</xref>), which were used to form the ancA8/A9 complex. AncA8 and ancA9 had average posterior probabilities of 0.88 and 0.83, with sequence similarities to human A8 and A9 of 66% and 64%, respectively (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Average posterior probabilities in this range have been previously described as medium confidence reconstructions, with reconstructions characterized by others having average posterior probabilities as low as 0.7 (<xref ref-type="bibr" rid="bib23">Eick et al., 2016</xref>). We confirmed that each protein was folded and had secondary structure content similar to that of human A8/A9 using far-UV circular dichroism (CD) spectroscopy (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p><p>We then measured the antimicrobial activity of ancA8/A9 against <italic>S. epidermidis.</italic> We observed a potent reduction in <italic>S. epidermidis</italic> growth comparable to that of human A8/A9 (<xref ref-type="fig" rid="fig1">Figure 1c–d</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). To test for the robustness of this finding to phylogenetic uncertainty, we also tested the antimicrobial activity of an AltAll (<xref ref-type="bibr" rid="bib23">Eick et al., 2016</xref>) reconstruction of ancA8/A9 against <italic>S. epidermidis</italic> (altancA8/A9, <xref ref-type="fig" rid="fig1">Figure 1c–d</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). In this reconstruction, we swapped all ambiguously reconstructed amino acid positions for their second-most likely state (see methods). AncA8/A9 and altancA8/A9 differ by 27 amino acids total (10 between ancA8 and altancA8 and 17 between ancA9 and altancA9 - <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). AltancA8/A9 exhibited antimicrobial activity against <italic>S. epidermidis</italic> similar to opossum A8/A9: it delayed growth but did not ultimately limit bacterial carrying capacity. While the hexahistidine site residues are conserved in ancA8/A9 and altancA8/A9 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), it appears that a subset of the ambiguously reconstructed 27 residues are important for A8/A9 antimicrobial activity, perhaps affecting the orientation and/or affinity of the hexahistidine metal-binding site.</p><p>Taken together, the antimicrobial activity of modern mammalian A8/A9 complexes (human, mouse, and opossum) and the antimicrobial activity of the reconstructed ancA8/A9 complex suggest that A9s evolved to form the antimicrobial A8/A9 complex in the ancestor of mammals.</p></sec><sec id="s2-2"><title>A9s evolved potent proinflammatory activity from a weakly active amniote ancestor</title><p>We next sought to determine when A9s evolved potent proinflammatory activity via activation of TLR4. Our previous work revealed that human A9 potently activates not only human TLR4 in functional assays, but also opossum and chicken TLR4 (<xref ref-type="fig" rid="fig2">Figure 2a</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). In contrast, chicken MRP126, the sauropsid ortholog of A9s, was found to be a weak activator of all TLR4s, including chicken TLR4. Both human and opossum A9 activate chicken TLR4 better than chicken MRP126 does. Two possibilities are consistent with these observations. Either mammalian A9s evolved enhanced proinflammatory activity from a less active amniote ancestral state, or A9s maintained a potent ancestral activity that was lost by chicken MRP126.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>A9s gained proinflammatory activity from a weakly proinflammatory ancestor.</title><p>(<bold>a</bold>) Schematic of previously measured proinflammatory activity of S100s against various TLR4s. Species labels on x and y-axes of heatmap are the same as <xref ref-type="fig" rid="fig1">Figure 1</xref>. Heatmap coloring is scaled to match 2 μM S100 activity levels measured in supplementary figure S2 of <xref ref-type="bibr" rid="bib61">Loes et al. (2018)</xref>. (<bold>b</bold>) and (<bold>c</bold>) NF-κB production of human and opossum TLR4 in response to treatment with modern and ancestral S100 proteins. Bars represent average of &gt;3 biological replicates, error bars are standard error of the mean. All values are background-subtracted and normalized to LPS positive control (see methods).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Human TLR4 activation data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Opossum TLR4 activation data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig2-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Analysis of S100 protein LPS contamination.</title><p>Top panel: Activity of LPS (0.2 ng/µl) against human (left) and opossum TLR4 (right) is inhibited by the addition of Polymyxin B (PB, 0.2 µg/µl). Middle and bottom panels: S100 activation of human (middle) and opossum (bottom) TLR4 with no PB, 0.2 µg/µl PB (+) and 0.25 µg/µl PB (++). No-PB data were not collected for hA9, opA9, and opA9 M60F against opossum TLR4 (bottom panel). Data were background-subtracted using the LPS + PB control and normalized to LPS activity against either human or opossum TLR4. Error bars are standard deviation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Dose curves for S100 activation of human TLR4.</title><p>Points are the average of &gt;3 biological replicates each consisting of 3 technical triplicates, error bars are standard error of the mean. An asterisk (*) indicates a concentration at which a single biological replicate was measured. Data were background-subtracted using the LPS + PB control and normalized to LPS activity against human TLR4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Dose curves for S100 activation of opossum TLR4.</title><p>Points are the average of &gt;3 biological replicates each consisting of 3 technical triplicates, error bars are standard error of the mean. An asterisk (*) indicates a concentration at which a single biological replicate was measured. Data were background-subtracted using the LPS + PB control and normalized to LPS activity against opossum TLR4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig2-figsupp3-v2.tif"/></fig></fig-group><p>To differentiate between these two possibilities, we determined the ancestral proinflammatory activity of these proteins. We used ASR to reconstruct the shared amniote ancestor of A9s, A8s, A12s, and MRP126s. This group of proteins is known collectively as the ‘calgranulins’, so we will refer to this ancestral protein as ancCG (ancestor of calgranulins). We also constructed an alternate, ‘alt All’ version of this ancestor (altancCG, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1</xref>), which differed from ancCG by eight amino acids. The average posterior probability of ancCG was 0.86 (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). We also expressed and purified ancA9 and altancA9 – the A9 subunits from the ancestral A8/A9 complexes described above. We confirmed that each protein was folded and had secondary structure content similar to that of modern S100s using far-UV CD spectroscopy (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p><p>We then tested modern and ancestral S100s for activity against human TLR4. Following previous work, (<xref ref-type="bibr" rid="bib90">Vogl et al., 2007</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Anderson et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Ehrhardt et al., 2006</xref>) we transiently transfected HEK293T cells with plasmids encoding TLR4 and its species-matched cofactors MD-2 and CD14, added purified S100 proteins to the growth media, and then measured output of luciferase under control of an NF-κB promoter. Consistent with previous results, (<xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>) we found that human A9 potently activated human TLR4, resulting in high levels of NF-κB production (<xref ref-type="fig" rid="fig2">Figure 2b</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s2">2</xref>). Human A8/A9 and opossum A9 exhibited much weaker activity against human TLR4. Lastly, we tested ancA9, altancA9, ancCG, and altancCG for activity against human TLR4 and observed weak or no activation for each ancestral protein. This result is unsurprising, as we previously found that human TLR4 is more specific than other amniote TLR4s: human TLR4 is activated much more potently by human A9 than by any other S100 protein (<xref ref-type="fig" rid="fig2">Figure 2a–b</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). In contrast, TLR4s from other species (mouse, opossum, and chicken) appear to be more promiscuous and can be activated similarly by S100s from various species (<xref ref-type="fig" rid="fig2">Figure 2a</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). This is consistent with lineage-specific coevolution between human TLR4 and human A9 – a confounding variable that makes assessment of ancestral S100 protein proinflammatory activity difficult using human TLR4.</p><p>We predicted that opossum TLR4 would be a better protein to probe ancestral S100 proinflammatory function because opossum TLR4 is broadly activated by A9s across mammals and gives little indication of lineage-specific coevolution (<xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). We therefore tested the proinflammatory activity of ancA9, ancCG, and their corresponding alternate reconstructions against opossum TLR4. Corroborating previous results, human A9 strongly activated opossum TLR4, while opossum A9 activity was approximately half that of human A9 (<xref ref-type="fig" rid="fig2">Figure 2c</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s3">3</xref>). AncA9 and altancA9 activated opossum TLR4 to the same extent as opossum A9. AncCG and altancCG were the weakest activators of opossum TLR4, with activity approximately 25% or less than that of human A9.</p><p>These findings suggest that A9s evolved enhanced proinflammatory activity early in mammals from a weakly proinflammatory amniote ancestor, while A8/A9s and chicken MRP126 maintained weak, ancestral proinflammatory activity.</p></sec><sec id="s2-3"><title>A9s evolved proteolytic susceptibility from a proteolytically resistant amniote ancestor</title><p>We next sought to determine when the differential proteolytic susceptibility of A9 and A8/A9 evolved. We used a simple in vitro assay to monitor S100 protein degradation over time in the presence of proteinase K, a potent non-specific serine protease (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Proteinase K was chosen both because of its low specificity and to mimic other serine proteases that A9 and A8/A9 encounter when released from neutrophils during an inflammatory response (<xref ref-type="bibr" rid="bib40">Henry et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Stapels et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Kessenbrock et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Heutinck et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Fu et al., 2018</xref>). Proteolytic decay rates were estimated by fitting a single exponential decay function to the data (<xref ref-type="fig" rid="fig3">Figure 3b</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s4">4</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>A9s lost proteolytic resistance from a proteolytically resistant amniote ancestor.</title><p>(<bold>a</bold>) In vitro proteolytic resistance assay showing SDS-PAGE gel of S100 protein degradation via proteinase K over time. Gels were quantified using densitometry and normalized to the undigested protein band intensity. (<bold>b</bold>) A single exponential decay model was globally fit to the data to quantify decay rates. Points are biological replicates, lines are model fit to data. (<bold>c</bold>) S100 protein proteolysis rates mapped onto schematized S100 phylogeny. X-axis cartoon labels same as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Circles indicate proteolytic susceptibility (faded/dashed) and resistance (solid), with predicted resistance shown for ancA8, ancA9, and ancCG nodes. (<bold>d</bold>) Decay rates for ancestrally reconstructed proteins, with gels shown on the right. For panels (<bold>c</bold>) and (<bold>d</bold>), error bars are the square root of the diagonalized covariance matrix from the fit and the y-axis is in log scale. (<bold>e</bold>) Summary model for proposed evolution of A9 and A8/A9 innate immune properties. Box around A8/A9 and A9 indicate location in tree (ancestor of therian mammals) where immune functions evolved.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Proteolytic susceptibility data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Survey of proteolytic susceptibility across modern S100 proteins.</title><p>Blue dots are biological replicates, orange line is a single exponential decay fit (see methods). Protein is listed at the top. Pixel intensity was quantified by densitometry from SDS-PAGE gels.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Comparison of proteolytic susceptibility for A8s, A9s, and A8/A9 complexes across mammals.</title><p>Blue dots are biological replicates, orange line is a single exponential decay fit (see methods). Protein is listed at the top. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer time points were collected for proteins with slower degradation rates (see x-axis).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Comparison of proteolytic susceptibility for ancestrally reconstructed S100s.</title><p>Blue dots are biological replicates, orange line is a single exponential decay fit (see methods). Protein is listed at the top. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer time points were collected for proteins with slower degradation rates (see x-axis).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Comparison of proteolytic S100 protein mutants at position 63.</title><p>Blue dots are biological replicates, orange line is a single exponential decay fit (see methods). Protein is listed at the top. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer time points were collected for proteins with slower degradation rates (see x-axis).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig3-figsupp4-v2.tif"/></fig></fig-group><p>Human A8/A9 has been described as extremely resistant to proteases (<xref ref-type="bibr" rid="bib62">Nacken and Kerkhoff, 2007</xref>); however, it has not been compared to S100 proteins besides human A8 and A9. To establish a baseline expectation for S100 protein proteolytic resistance, we characterized the proteolytic resistance of a broad set of human S100s against proteinase K. As previously shown, (<xref ref-type="bibr" rid="bib62">Nacken and Kerkhoff, 2007</xref>) human A9 and A8 alone were rapidly proteolytically degraded, while the human A8/A9 complex exhibited strong resistance (<xref ref-type="fig" rid="fig3">Figure 3c</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s2">2</xref>). Under our conditions, the degradation rates for human A8 and A9 were approximately three orders of magnitude faster than that of the human A8/A9 heterocomplex. We then characterized closely related protein human S100A12 (A12), the chicken ortholog MRP126, and six distantly related human S100s (<xref ref-type="bibr" rid="bib94">Wheeler et al., 2016</xref>). Human A12, chicken MRP126, and five out of six more distantly related human S100s exhibited intermediate to strong proteolytic resistance, each degrading 1–2 orders of magnitude slower than human A8 or A9 but, on average, one order of magnitude faster than human A8/A9 (<xref ref-type="fig" rid="fig3">Figure 3c</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s2">2</xref>). Notably, human A12 and chicken MRP126 formed predominantly homodimers by SEC MALS under these conditions (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), indicating that higher-order oligomerization (&gt;2 subunits) isn’t required for S100 proteolytic resistance. Lastly, human A14 degraded faster than A9 or A8. This protein is evolutionarily distant (<xref ref-type="bibr" rid="bib94">Wheeler et al., 2016</xref>) and therefore likely reflects independent evolution of this property. Taken together, these data show that the A8/A9 complex, A9, and A8 indeed fall at the extremes of human S100 proteolytic resistance; human A9 and A8 are among the fastest-degrading S100s tested, while human A8/A9 is one of the slowest.</p><p>To test whether A9 and A8 proteolytic susceptibility and A8/A9 resistance are conserved across mammals, we characterized mouse and opossum A9, A8, and A8/A9 for proteolytic resistance. Mouse A9 and A8 were found to be highly proteolytically susceptible and mouse A8/A9 strongly proteolytically resistant, matching the pattern observed for their human counterparts (<xref ref-type="fig" rid="fig3">Figure 3c</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Opossum A9 and A8 were also highly proteolytically susceptible, while opossum A8/A9 was resistant (<xref ref-type="fig" rid="fig3">Figure 3c</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). This indicates that the susceptibility of A9s and A8s and the resistance of A8/A9 complexes is conserved across mammals.</p><p>When mapped onto the S100 phylogeny, the most parsimonious explanation for these data is that the shared amniote ancestor—ancCG—was proteolytically resistant (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). In this scenario, A12s, MRP126s, and A8/A9s conserved ancestral resistance, while A9s and A8s independently lost resistance early in mammals. Alternatively, ancCG could have been proteolytically susceptible. This would mean that A9s and A8s maintained an ancestral susceptibility, while MRP126s, A12s, and A8/A9s each evolved novel proteolytic resistance.</p><p>To distinguish between these possibilities, we characterized ancestrally reconstructed S100s for proteolytic resistance. AncCG and altancCG exhibited extremely high proteolytic resistance (<xref ref-type="fig" rid="fig3">Figure 3d</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>), with degradation rates 3–4 orders of magnitude slower than modern A8s or A9s and approximately one order of magnitude slower than modern A8/A9s. AncA8/A9 and altancA8/A9 also demonstrated high proteolytic resistance, with degradation rates approximately 2–3 orders of magnitude slower than A8s and A9s and comparable to modern A8/A9 complexes (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Together, these data paint a consistent picture: the amniote ancestor of A9s, ancCG, was strongly resistant to proteolytic degradation. Modern A9s and A8s lost proteolytic resistance from an ancestrally resistant state, while modern A12s, A8/A9 complexes, and MRP126s maintained the ancestral proteolytic resistance (<xref ref-type="fig" rid="fig3">Figure 3e</xref>).</p><p>Finally, we sought to better resolve when A9s acquired proteolytic susceptibility. We hypothesized that this occurred in the ancestor of mammalian A9s before the divergence of therian mammals and marsupials. To test this hypothesis, we measured the proteolytic susceptibility of therian mammalian ancA9 and found that it degraded rapidly (<xref ref-type="fig" rid="fig3">Figure 3</xref>). However, its alternative reconstruction (altancA9), was slow to degrade, with a rate two orders of magnitude slower than ancA9 and comparable to other highly resistant S100s. Because the descendants of ancA9 all exhibit proteolytic susceptibility (<xref ref-type="fig" rid="fig3">Figure 3</xref>), the simplest explanation is that altancA9 is a low-quality reconstruction that does not capture the properties of the historical protein. Alternatively, proteolytic susceptibility could have been independently acquired along marsupial and placental mammal lineages.</p></sec><sec id="s2-4"><title>A single substitution had pleiotropic effects on A9 proinflammatory activity and proteolytic resistance</title><p>We found above that A9 evolved to form the antimicrobial A8/A9 complex, gained potent proinflammatory activity, and lost proteolytic resistance over the narrow evolutionary interval after the divergence of mammals and sauropsids but before the divergence of placental mammals and marsupials. We next sought to determine how A9 evolved its antimicrobial and proinflammatory activities and lost proteolytic resistance.</p><p>The mechanism by which A9 evolved to form the antimicrobial A8/A9 complex is straightforward. After ancCG duplicated, additional histidines accumulated in the mammalian A8 and A9 ancestors that created the antimicrobial hexahistidine metal-binding site in the A8/A9 complex (<xref ref-type="fig" rid="fig3">Figure 3e</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). A8s acquired one additional histidine while retaining the three histidines present in ancCG, while A9s acquired two additional histidines via acquisition of a C-terminal extension (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). While A9s evolved five of the six histidines composing the hexahistidine metal-binding site, this was not sufficient to convey potent antimicrobial activity (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Instead, preservation of A8/A9 heterocomplex formation resulted in proper assembly of the complete antimicrobial hexahistidine site early in mammals. The quantitative difference between ancA8/A9 and altancA8/A9 antimicrobial activity suggests that other amino acid changes tuned the antimicrobial activity of the molecule, but the core functionality is determined by whether the six histidine residues were present. This is independently supported by Brunjes Brophy et al., who showed that mutating the two C-terminal histidines in A9 is sufficient to strongly decrease the A8/A9 complex’s antimicrobial activity (<xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>).</p><p>The mechanisms by which A9s gained proinflammatory activity and lost proteolytic resistance are less obvious, particularly because the mechanism by which A9 activates TLR4 is not well understood. We reasoned that we could identify functionally important amino acid substitutions by focusing on the evolutionary interval over which these properties evolved. We therefore compared the sequences of ancCG (weakly proinflammatory and resistant to proteolytic degradation) and ancA9 (potently proinflammatory and susceptible to proteolytic degradation). We further narrowed down sequence changes of interest by looking for residues conserved in modern A9s (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Finally, we focused on amino acid changes in helix III of A9, as this region is thought to be important for A9 activation of TLR4 based on in vitro binding studies and in silico docking studies (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>). Only one historical amino acid substitution met all three criteria: position 63 (human A9 numbering). This residue is a phenylalanine in both ancCG and altancCG, is conserved as a phenylalanine in 95% of modern A8s and A12s and has been substituted for a methionine or leucine (M/L) in 97% of A9s (<xref ref-type="fig" rid="fig4">Figure 4a</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A single historical substitution affects A9 proinflammatory activity and proteolytic resistance without affecting A8/A9 proteolytic resistance or antimicrobial activity.</title><p>(<bold>a</bold>) Schematic S100 phylogenetic tree with the amino acid state of position 63 shown at key nodes. Wedges represent clades, colored as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Lines indicate proteolytic susceptibility (faded/dashed) and resistance (solid). Circles indicate characterized ancestors. Amino acid labels represent maximum likelihood state/alternate amino acid state for position 63 at ancestral nodes, while labels at clade tips represent percent conservation across modern S100 protein sequences. (<bold>b–c</bold>) NF-κB production of S100 point mutants at position 63 against human (<bold>b</bold>) and opossum (<bold>c</bold>) TLR4. (<bold>d</bold>) Proteolysis rates for S100 point mutants at position 63 (human A9 numbering). Error bars and y-axis are the same as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. (<bold>e</bold>) Antimicrobial activity of hA9 and hA8/A9 with and without M63F mutation against <italic>S. epidermidis.</italic> Axes and error bars same as in <xref ref-type="fig" rid="fig1">Figure 1d</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Human TLR4 activation data with point mutants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Proteolytic susceptibility data with point mutants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig4-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Antimicrobial activity data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig4-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Opossum TLR4 activation data with point mutants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig4-data4-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Changes at position 63 correlate with A9 proinflammatory activity and proteolytic resistance.</title><p>S100 protein sequences are grouped into proteolytically susceptible (top) or resistant and potently proinflammatory (red text) or not (black text). Only the first 90 residues out of 114 total were examined as the disordered A9 tail (residues ~ 93–114) are highly variable and the tail is dispensable for A9 proinflammatory activity. Residues are colored when found to be the consensus residue for a column.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Comparison of human A9 and human A9 M63F proteolytic resistance against human proteases.</title><p>Blue dots are biological replicates, orange line is a single exponential decay fit (see methods). Protein is listed at the top of each graph. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer time points were collected for proteins with slower degradation rates (see x-axis). Representative SDS-PAGE gels are shown for 0–120 min digestion with each protease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig4-figsupp2-v2.tif"/></fig></fig-group><p>We hypothesized that reverting this site to its amniote ancestral state—M63F—might affect A9 proinflammatory activity. We mutated this position to a phenylalanine in human A9 and opossum A9 and tested each protein for TLR4 activation. Strikingly, we found that introducing M63F into human A9 severely compromised its ability to activate human TLR4 (<xref ref-type="fig" rid="fig4">Figure 4b</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). This was also true for opossum A9: introduction of M63F (human numbering) strongly decreased opossum A9 activation of opossum TLR4 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). We next introduced the forward substitution, F63M, into ancCG and tested its proinflammatory activity against opossum TLR4. We observed a modest increase in ancCG activity with the F63M substitution, with activity comparable to that of opossum A9 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>).</p><p>For most proteins we studied, the amino acid at position 63 did indeed play an important role in determining the pro-inflammatory activity of A9. The effects of toggling position 63 between Met and Phe were not, however, universal. We introduced M63F into ancA9 and observed no change in proinflammatory activity (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Further, altancA9 has a Phe at position 63 but activates TLR4 in the assay (<xref ref-type="fig" rid="fig2">Figure 2c</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Thus, while position 63 is an important contributor to activity in modern A9s, other substitutions were also important for the transition from a weakly pro-inflammatory ancestor to the modern set of potently pro-inflammatory A9s.</p><p>Because A9s lost proteolytic resistance and gained proinflammatory activity over the same evolutionary time interval, we reasoned that the F63M substitution might have also played a role in A9 loss of proteolytic resistance. To test this, we characterized the proteolytic resistance of human A9 M63F and ancA9 M63F. Strikingly, reversion of this single mutation rendered both ancA9 and human A9 strongly resistant to proteolytic degradation, decreasing their respective degradation rates by 1–2 orders of magnitude and approaching the degradation rates of ancCG and various A8/A9 complexes (<xref ref-type="fig" rid="fig4">Figure 4d</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). To relate these findings to proteases that A9 might encounter at sites of inflammation, we also measured the proteolytic resistance of human A9 and human A9 M63F against two neutrophil-specific proteases – cathepsin G and neutrophil elastase (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Neutrophils release these proteases along with A9 at sites of inflammation, often through Neutrophil Extracellular Traps (NETs) (<xref ref-type="bibr" rid="bib40">Henry et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Stapels et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Kessenbrock et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Heutinck et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Janoff, 1972</xref>; <xref ref-type="bibr" rid="bib50">Jerke et al., 2015</xref>; <xref ref-type="bibr" rid="bib67">O'Donoghue et al., 2013</xref>). We found that M63F decreased the rate of human A9 degradation in the presence of cathepsin G and neutrophil elastase in vitro by approximately one order of magnitude, matching our results using proteinase K (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Lastly, we tested the effect of the forward mutation – F63M – on ancCG proteolytic resistance. We observed no change in resistance for ancCG F63M, indicating that additional substitutions were required to render ancA9 proteolytically susceptible. Together these data show that a single historical reversion is sufficient to render A9s proteolytically resistant, indicating that this position played a role in the loss of A9 proteolytic resistance early in therian mammals.</p></sec><sec id="s2-5"><title>The pleiotropic substitution minimally affects the A8/A9 complex</title><p>A primary goal of this study was to understand the role of pleiotropy in the evolution of multifunctionality. M63F clearly has pleiotropic effects on A9, altering both its proinflammatory activity and proteolytic resistance (<xref ref-type="fig" rid="fig4">Figure 4b–d</xref>). We next asked whether introducing M63F would pleiotropically affect the antimicrobial A8/A9 complex. Position 63 is somewhat distant from the A8/A9 interface and the antimicrobial hexahistidine site (~10 Å in the manganese-bound A8/A9 crystal structure) (<xref ref-type="bibr" rid="bib19">Damo et al., 2013</xref>); we therefore hypothesized that M63F should not affect A8/A9 complex formation or function. To test this hypothesis, we introduced M63F into human A8/A9 and tested it for oligomeric state, proteolytic resistance, and antimicrobial activity against <italic>S. epidermidis.</italic> As predicted, human A8/A9 M63F predominantly formed a heterotetramer in the presence of calcium by SECMALS with a molecular weight similar to that of wildtype human A8/A9 (48.7 ± 4.2 kDa – <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). We found that human A8/A9 M63F was also strongly resistant to proteolytic degradation, similar to human A8/A9 (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). Lastly, M63F had minimal impact on human A8/A9 antimicrobial activity against <italic>S. epidermidis</italic>, retaining potent antimicrobial activity (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). In contrast, neither human A9 nor human A9 M63F were antimicrobial against <italic>S. epidermidis</italic> (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). These findings suggest that this single amino acid position had important effects on the evolution of A9 activation of TLR4 and loss of proteolytic resistance without significantly impacting A8/A9 oligomeric state, proteolytic resistance, or antimicrobial activity.</p></sec><sec id="s2-6"><title>M63F increases protein thermodynamic stability and decreases unfolding rate of human A9</title><p>We next asked what effect M63F has on the biophysical properties of human A9. Residue 63 sits in the middle of helix III of A9, pointing inward toward helix II, and is neither a core residue nor fully surface-exposed (<xref ref-type="fig" rid="fig5">Figure 5a</xref>; <xref ref-type="bibr" rid="bib48">Itou et al., 2002</xref>). Based on the published structure of human A9, (<xref ref-type="bibr" rid="bib48">Itou et al., 2002</xref>) a Phe at position 63 could be plausibly tolerated without a steric clash. Using circular dichroism (CD) spectroscopy, we found that the bulk secondary structure content of human A9 M63F was similar to that of hA9 (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). We measured the oligomeric state of human A9 M63F by SEC MALS and found that it predominantly forms a homodimer in solution similarly to human A9, with no detectable monomers or larger oligomers (<xref ref-type="fig" rid="fig5">Figure 5c and f</xref>). These data together indicate that M63F does not significantly alter human A9’s secondary structure or oligomeric state.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>M63F increases human A9 apparent stability by decreasing its unfolding rate.</title><p>(<bold>a</bold>) Crystal structure of hA9 (PDB entry 1irj) (<xref ref-type="bibr" rid="bib48">Itou et al., 2002</xref>). Cartoon depiction left, surface view right. Calcium ions are blue spheres. M63 is highlighted in red – two total for homodimeric A9. (<bold>b</bold>) Far-UV circular dichroism (CD) spectroscopy scans of hA9 and hA9 M63F. Data represent average of 3 scans. (<bold>c</bold>) SEC MALS analysis of hA9 and hA9 M63F oligomeric state. Solid lines are refractive index (left y-axis), points and molecular weights in table below represent molar mass calculated from light scattering detectors using ASTRA software (right y-axis - see methods). (<bold>d</bold>) Equilibrium chemical denaturation (urea) of 5 µM hA9 and hA9 M63F monitored by CD at 222 nm. Solid lines represent two-state unfolding model fit to data. (<bold>e</bold>) Kinetics of hA9 and hA9 M63F unfolding via chemical denaturation (guanidinium hydrochloride). Graph depicts one representative unfolding experiment. (<bold>f</bold>) Thermodynamic parameters estimated from (<bold>d</bold>) and molecular weights estimated from (<bold>c</bold>). Errors are standard deviations calculated from fit (see methods).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>CD spectroscopy data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig5-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>CD unfolding kinetics data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig5-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Chemical denaturation data by CD.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig5-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Chemical denaturation of hA9 and hA9 M63F.</title><p>Chemical denaturation experiments using urea (left) and guanidinium hydrochloride (right). Graphs represent &gt;3 replicates. Human A9 is shown in purple, A9 M63F in red. An apparent two-state unfolding model was fit to the data to estimate thermodynamic parameters, shown as a solid line.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Unfolding kinetics of hA9 and hA9 M63F.</title><p>Time course measurement of hA9 (top) and hA9 M63F (bottom) unfolding upon addition of 6M gdn-HCl. Each curve is a single replicate at one concentration, monitoring CD signal at 222 nm (y-axis).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig5-figsupp2-v2.tif"/></fig></fig-group><p>We then examined whether M63F alters the stability of human A9. We measured equilibrium unfolding curves for human A9 and human A9 M63F using CD spectroscopy and chemical denaturation via urea. We found that M63F appears to stabilize human A9, increasing the apparent free energy of unfolding by more than four kcal/mol and shifting the C<sub>m</sub> by ~2M urea (<xref ref-type="fig" rid="fig5">Figure 5d and f</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). We also measured the unfolding kinetics of human A9 and human A9 M63F in the presence of calcium by spiking protein directly into 6M guanidinium hydrochloride (gdn-HCl) denaturant and monitoring its unfolding rate by CD spectroscopy. Strikingly, human A9 M63F takes several minutes to unfold under these conditions, while human A9 unfolds immediately within the dead time of the experiment (<xref ref-type="fig" rid="fig5">Figure 5e–f</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). We note that the folding pathway for A9 is complex and almost certainly not two-state—calcium binding, monomer folding, and dimerization all contribute—and thus we cannot reliably determine how M63F affects the stability of each of these potential folding intermediates. The large increase in apparent stability and unfolding rate suggests, however, that the mutation stabilizes some aspect of the folded structure.</p></sec><sec id="s2-7"><title>Proteolysis is not required for A9 activation of TLR4</title><p>The work above identified a mutation that, when introduced into human A9, increases the stability of the protein while also potently compromising its ability to activate TLR4. The mutation is not at a surface position and is therefore not likely a direct participant in the A9/TLR4 protein/protein interface. Further, the same mutation dramatically decreases the proteolytic susceptibility of the protein. One simple way to explain these observations would be if the proteolytic susceptibility itself was the feature that evolved to allow activation of TLR4. This would be consistent with a previous observation that proteolytic products of A9 activate TLR4 (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>).</p><p>To test whether proteolysis itself was sufficient for activity, we engineered an alternate variant of A9 that was proteolytically susceptible. We introduced the M63A mutation into human A9, anticipating that the short alanine sidechain would not have the stabilizing effect of M63F. As expected, human A9 M63A was highly susceptible to proteolytic degradation, similar to wildtype human A9 (<xref ref-type="fig" rid="fig6">Figure 6a</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). We reasoned that if proteolysis is the primary determinant of A9 activation of TLR4, then proteolytically susceptible human A9 M63A should potently activate TLR4. Human A9 M63A, however, exhibited diminished proinflammatory activity, similar to human A9 M63F (<xref ref-type="fig" rid="fig6">Figure 6b</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). This indicates that the methionine at position 63 is important for A9 activation of TLR4. Further, we quantified the amount of human A9, human A9 M63F, and human A9 M63A before and after measuring TLR4 activity and observed no decrease in the amount of full-length protein remaining for wildtype human A9 or either mutant by western blot (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). This indicates that A9 is not digested by extracellular proteases over the course of the ex vivo assay and that proteolysis is not necessary for A9 activation of TLR4.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Proteolysis is not required for A9 activation of TLR4.</title><p>(<bold>a</bold>) Proteolytic decay rates for human point mutants at position 63. Error bars and axes are the same as in <xref ref-type="fig" rid="fig3">Figure 3</xref>. (<bold>b</bold>) NF-κB production of human TLR4 in response to treatment with hA9, hA9 M63F, and hA9 M63A. Error bars the same as in <xref ref-type="fig" rid="fig2">Figure 2</xref>. (<bold>c</bold>) Western blot of hA9 and position 63 point mutants before and after proinflammatory activity assay. Left bands represent 10 and 15 kDa ladder. (<bold>d</bold>) NF-κB production of human TLR4 in response to hA9 and hA9 M63F pre-proteolyzed with proteinase K for increasing amounts of time. Points are biological replicates and are the average of three technical replicates. Western blots below depict the amount of full-length A9 remaining over time. Left blot shows antibody sensitivity to A9, right shows digestion time course samples. Ladder and antibody same as in (<bold>c</bold>).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Proteolytic degradation data with hA9 M63A data included.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>TLR4 activation data with M63A included.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54100-fig6-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54100-fig6-v2.tif"/></fig><p>Although proteolysis does not appear to be a requirement for TLR4 activation, this does not rule out that proteolysis could increase A9 proinflammatory activity by releasing proinflammatory fragments of A9. To test for this possibility, we treated human A9 with agarose-immobilized proteinase K for increasing amounts of time, removed the protease, and then measured the proinflammatory activity of A9 degradation products (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). If proteolytic products of A9 are the most proinflammatory form of the protein, we might expect to observe a spike in TLR4 activation upon A9 digestion. Instead, we observed a steady decrease in human A9 activity with increasing digestion time. This suggests that full-length human A9 is the most potent activator of TLR4.</p><p>We did observe moderate activity for proteolytic products of human A9, as previously shown (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>). After 30 min of digestion, no detectable full-length A9 remains by western blot (&lt;30 ng, <xref ref-type="fig" rid="fig6">Figure 6d</xref>), but NF-κB production is still quite high, revealing that smaller fragments of A9 are sufficient to provide some degree of activation of TLR4. This raised the possibility that part of M63F’s deleterious effect on proinflammatory activity could be to limit the release of active proteolytic fragments of A9. To test this, we also measured human A9 M63F activation of TLR4 after digestion for multiple hours (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). Unlike wildtype, however, fragments of human A9 M63F did not activate TLR4—even after being liberated by the protease. This strongly suggests that the historical mutation induced a change in the native structure or dynamics of the molecule to bring about increased activity, independent of its effect on proteolytic susceptibility.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The work presented here provides insight into how the multifunctional protein A9 evolved critical innate immune functions. We find that mammalian A9s gained enhanced proinflammatory activity and lost proteolytic resistance from a weakly proinflammatory, proteolytically resistant amniote ancestor. A single substitution played a key role in the evolution of these properties without significantly affecting the antimicrobial activity of the A8/A9 heterocomplex. This work contributes to our mechanistic understanding of how A9 activates TLR4 to drive inflammation and clarifies the role of proteolysis in A9 innate immune function.</p><sec id="s3-1"><title>Innate immune functions of A9 continued to evolve within the mammals</title><p>Our data suggest that the proinflammatory and antimicrobial activities of A9 and the A8/A9 complex have undergone further optimization in placental mammals since these functions evolved. While the histidines composing the high-affinity metal-binding site of A8/A9 complexes are conserved, we observed differences in antimicrobial potency for different A8/A9 complexes. In particular, human A8/A9 is one of the most potently antimicrobial A8/A9 complexes characterized. This suggests that further optimization of the metal-binding site has occurred in along the human lineage within mammals. We also observed differences in activation of TLR4 by different A9s—human A9 is a potent, promiscuous activator of TLR4s from multiple species, while earlier-diverging A9s and other S100s exhibit weaker proinflammatory activity (<xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). Future studies are necessary to understand how, mechanistically, later-diverging A9s and A8/A9 complexes have optimized these critical innate immune functions.</p></sec><sec id="s3-2"><title>Why did A9s lose proteolytic resistance?</title><p>While proteolysis is not required for A9 activation of TLR4, it remains unclear why A9s lost proteolytic resistance. We suggest three possibilities. The first is that loss of proteolytic resistance in A9s was simply a byproduct of evolving proinflammatory activity. No A9 characterized in this study, with the exception of the alternate reconstruction of ancA9, is both proteolytically resistant and potently proinflammatory. This indicates that the molecular requirements for A9 proteolytic resistance may be incompatible with those required for A9 activation of TLR4: A9s may have gained proinflammatory activity at the expense of proteolytic resistance. A second possibility is that A9 proteolytic susceptibility is being maintained to actively remove proinflammatory A9 from the cell and retain the antimicrobial A8/A9 complex. The last possibility for A9 loss of proteolytic resistance is adaptive constraint. There could be selection for some property of A9 or A8/A9 that we did not measure that is incompatible with A9 proteolytic resistance.</p><p>While we cannot explicitly distinguish between each of these possibilities, the end result is that A9s lost proteolytic resistance from a resistant ancestor. As A9s activate TLR4 in the protease-rich extracellular space, the functional result of A9 loss of proteolytic resistance is that A9s evolved a proteolytic ‘timer’ concomitantly with evolving proinflammatory activity, all without affecting A8/A9 function.</p></sec><sec id="s3-3"><title>Novel mechanistic insight into A9 activation of TLR4</title><p>Our findings suggest new directions for understanding how A9 potently activates TLR4. TLR4-driven inflammation has been the focus of intense study for over 20 years, (<xref ref-type="bibr" rid="bib52">Källberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Laouedj et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Gao et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Anderson et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Ibrahim et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Nagai et al., 2002</xref>; <xref ref-type="bibr" rid="bib74">Poltorak et al., 1998</xref>; <xref ref-type="bibr" rid="bib76">Prince et al., 2011</xref>) and the structural basis of TLR4 activation by exogenous agonists, such as the bacterial cell wall component lipopolysaccharide (LPS), is well understood (<xref ref-type="bibr" rid="bib71">Park et al., 2009</xref>). In contrast, little is known about how A9 activates TLR4. We have shown here that proteolytic degradation appears dispensable for activation; however, smaller fragments of the protein are sufficient activate TLR4 (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Given the effect of mutating position 63 on A9 proinflammatory activity, we propose that the region surrounding it—helix III—is important for activity. This is independently supported by Vogl et al., who identified four pairs of double mutants within helix III (amino acids 64, 65, 73, and 77) that, when mutated to alanines in pairs, decrease A9 binding to TLR4 in vitro (<xref ref-type="bibr" rid="bib93">Vogl et al., 2018</xref>). Biophysical characterization of hA9 M63F (<xref ref-type="fig" rid="fig5">Figure 5</xref>) indicates that it is more stable and unfolds more slowly, yet it maintains its bulk secondary structure and oligomeric state. The simplest explanation for these data is that M63F is affecting some functionally important dynamic process of the protein, possibly mediated by helix III, that is critical for A9 activation of TLR4. The proteolytic susceptibility of A9s also supports this hypothesis, as proteolysis is a dynamic process that often relies on substrate flexibility and local unfolding events to proceed (<xref ref-type="bibr" rid="bib32">Guharoy et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Fontana et al., 1997</xref>; <xref ref-type="bibr" rid="bib45">Hubbard, 1998</xref>; <xref ref-type="bibr" rid="bib69">Ottesen, 1967</xref>; <xref ref-type="bibr" rid="bib47">Imoto et al., 1986</xref>). Damage-Associated Molecular Patterns (DAMPs) often interact with their targets via hydrophobic surfaces (<xref ref-type="bibr" rid="bib29">Garg et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Rubartelli and Lotze, 2007</xref>; <xref ref-type="bibr" rid="bib9">Bianchi, 2007</xref>); one possibility is that A9 undergoes a local unfolding event that exposes a hydrophobic surface to interact with TLR4. This would mean that studies of the native structure of A9 might not be sufficient to gain mechanistic understanding of how it activates TLR4. Further work is required to understand the nature of the active functional state of A9.</p></sec><sec id="s3-4"><title>Pleiotropic mutations can facilitate the evolution of multifunctionality</title><p>Finally, our results suggest a positive role for pleiotropy in the evolution of protein function. Pleiotropy is often viewed as a constraint on evolution: as functional complexity is added to a polypeptide sequence, it becomes increasingly challenging to introduce substitutions—and new functions—without perturbing existing ones (<xref ref-type="bibr" rid="bib59">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Stearns, 2010</xref>; <xref ref-type="bibr" rid="bib70">Paaby and Rockman, 2013</xref>; <xref ref-type="bibr" rid="bib39">He and Zhang, 2006</xref>; <xref ref-type="bibr" rid="bib72">Pavličev and Cheverud, 2015</xref>; <xref ref-type="bibr" rid="bib42">Hirano, 1999</xref>). Here, however, we find a single mutation that had beneficial pleiotropic effects on two important properties of A9: proinflammatory activity and proteolytic susceptibility. If A9 evolved potent proinflammatory activity without gaining susceptibility, it could potentially overstimulate inflammation simply by lingering in the extracellular milieu. Since both properties evolved at once, however, mammals evolved a proinflammatory molecule with a built-in ‘timer’: they gained a new inflammatory signal while avoiding potentially deleterious effects. This shows how pleiotropy can positively contribute to the evolution of new functions.</p><p>This same mutation, in contrast, had little pleiotropic effect on another functional state of A9: the A8/A9 complex. The antimicrobial activity of the A8/A9 complex was insulated from any pleiotropic effects from the mutation because proinflammatory and antimicrobial activities were partitioned between A9 and the A8/A9 complex, respectively. A mutation arose in the A9 amino acid sequence and is thus present in both A9 and A8/A9 states, but we only observe effects on the A9 state. This shows that pleiotropic constraint can be reduced when protein functions are partitioned amongst different protein states.</p><p>These findings reveal the diversity of pleiotropic roles that a single mutation can play. It further shows how the deleterious pleiotropic effects of mutations can be reduced by partitioning protein functions and properties into different functional states, thus enabling the acquisition, optimization, and expansion of new protein functions. Given the vast diversity of protein functional domains and protein-protein interactions in biology, we suspect that this is a common occurrence in the evolution of protein multifunctionality.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Software, algorithm</td><td valign="top">PAML4</td><td valign="top"><xref ref-type="bibr" rid="bib96">Yang, 2007</xref></td><td valign="top"/><td valign="top">For ancestral sequence reconstruction</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PhyML</td><td valign="top"><xref ref-type="bibr" rid="bib33">Guindon et al., 2010</xref></td><td valign="top"/><td valign="top">Published tree details in <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pETDuet-1 (plasmid)</td><td valign="top">Millipore</td><td valign="top">71146–3</td><td valign="top">For S100 protein recombinant expression</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pET His6 MBP TEV LIC (plasmid)</td><td valign="top">Addgene</td><td valign="top">29656</td><td valign="top">For S100 protein recombinant expression</td></tr><tr><td valign="top">Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="top">XL10-Gold <break/>Ultracompetent Cells</td><td valign="top">Agilent Technologies</td><td valign="top">200315</td><td valign="top">For plasmid storage/propagation</td></tr><tr><td valign="top">Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="top">Rosetta(DE3)pLysS Competent Cells</td><td valign="top">Millipore</td><td valign="top">70956–3</td><td valign="top">For recombinant protein expression</td></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">QuickChange Lightning Kit</td><td valign="top">Agilent Technologies</td><td valign="top">210519</td><td valign="top">For mutagenesis</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Proteinase K from <italic>Tritirachium album</italic></td><td valign="top">Sigma Aldrich</td><td valign="top">P2308</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Cathepsin G from human neutrophils</td><td valign="top">Athens research</td><td valign="top">16-14-030107</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Neutrophil elastase from human neutrophils</td><td valign="top">Millipore Sigma</td><td valign="top">324681</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Gelquant</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Python-based scripts for gel densitometry analysis</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens)</italic></td><td valign="top">HEK293T/17</td><td valign="top">ATCC CRL-11268</td><td valign="top"/><td valign="top">For transient transfections</td></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Human TLR4</td><td valign="top">Addgene</td><td valign="top">#13086</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Human CD14</td><td valign="top">Addgene</td><td valign="top">#13654</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">ELAM-Luc</td><td valign="top">Addgene</td><td valign="top">#13029</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Human MD2</td><td valign="top">DNASU repository</td><td valign="top">HsCD00439889</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Opossum TLR4</td><td valign="top">Genscript</td><td valign="top"><xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref> <break/>(UniProt #F6Y6W8)</td><td valign="top">In pcDNA3.1(+) backbone</td></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Opossum MD2</td><td valign="top">Genscript</td><td valign="top"><xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref> <break/>(UniProt #F6QBE6)</td><td valign="top">In pcDNA3.1(+) backbone</td></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">Opossum CD14</td><td valign="top">Genscript</td><td valign="top"><xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref> (NCB Accession #XP_007473804.1)</td><td valign="top">In pcDNA3.1(+) backbone</td></tr><tr><td valign="top">Biological sample (<italic>Escherichia coli)</italic></td><td valign="top">K-12 LPS</td><td valign="top">Invivogen</td><td valign="top">tlrl-eklps</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Dual-Glo luciferase assay system</td><td valign="top">Promega</td><td valign="top">E2940</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Polymyxin B</td><td valign="top">Sigma Aldrich</td><td valign="top">P4932-1MU</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Agarose-immobilized proteinase K</td><td valign="top">Sigma Aldrich</td><td valign="top">P9290-10UN</td><td valign="top"/></tr><tr><td valign="top">Antibody (mouse monoclonal)</td><td valign="top">Anti-S100A9 M13 Clone 1CD22 (monoclonal)</td><td valign="top">Abnova</td><td valign="top">H00006280-M13</td><td valign="top">WB 1:1000</td></tr><tr><td valign="top">Antibody (goat polyclonal)</td><td valign="top">IRDye Goat anti-mouse 800CW IgG (H+L)</td><td valign="top">Licor</td><td valign="top">926–32210</td><td valign="top">WB 1:10,000</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Phylogenetics and ancestral sequence reconstruction</title><p>We reconstructed ancestral sequences using a previously published a phylogenetic tree of S100 proteins containing 172 sequences from 30 amniote taxa (<xref ref-type="supplementary-material" rid="supp1">Supplementary files 1</xref>–<xref ref-type="supplementary-material" rid="supp2">2</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). We used PAML4 to generate maximum likelihood ancestors (marginal probability method) (<xref ref-type="bibr" rid="bib95">Yang et al., 1995</xref>; <xref ref-type="bibr" rid="bib96">Yang, 2007</xref>) using the previously-identified maximum likelihood (ML) substitution model (LG+Γ<sub>8</sub>) (<xref ref-type="bibr" rid="bib51">Jones et al., 1992</xref>) on the ML tree. To account for reconstruction uncertainty, we also generated ‘altAll’ versions of each ancestor (<xref ref-type="bibr" rid="bib23">Eick et al., 2016</xref>). We took every site in which the alternate reconstruction had a posterior probability &gt;0.20 and substituted that amino acid into the maximum-likelihood ancestor. These alternate reconstructions had an average of 12 sequence differences relative to the maximum-likelihood ancestors (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). They represent a ‘worst case’ reconstruction relative to our best, maximum likelihood reconstruction.</p><p>We also investigated the effect of topological uncertainty on our reconstructed ancestors. In the published phylogenetic analysis, A8s, A9s, A12s, and MRP126s all formed distinct and well-supported clades; however, the branching pattern between these four clades could not be resolved with high confidence (<xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>). To explore how this uncertainty altered our reconstructed ancestral proteins, we constructed all 15 possible topologies for the A8, A9, A12, and MRP126 clades—i.e ((A8,A9),(A12,MRP126)), ((A8,A12),(MRP126,A9)), etc.—while maintaining species-corrected, within-clade topologies. We then optimized the tree branch lengths and substitution rates for each tree using PhyML (<xref ref-type="bibr" rid="bib33">Guindon et al., 2010</xref>). Finally, we used PAML to reconstruct ancA9, ancCG, and ancA8 for all 15 possible arrangements of the MRP126, A12, A8, and A9 clades. The average number of sequence differences for ancestors reconstructed using different topologies was less than or equal to the number of sequence differences between the ML and altAll reconstructions (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Further, the sites that differed were a subset of those that differed between the ML and altAll reconstructions. Thus, the altAll reconstructions account for sequence changes due to both uncertainty given the ML tree and uncertainty due to topological uncertainty.</p></sec><sec id="s4-2"><title>Cloning and mutagenesis</title><p>All S100 genes in this study were purchased as synthetic constructs in pUC57 vectors from Genscript. S100 genes (A8s, A9s, A12s, MRP126s, and ancestrally reconstructed genes) were sub-cloned into a pETDuet-1 (pD) vector (Millipore). A8s, A12s, MRP126s, and ancCGs were cloned into multiple cloning site #1 (MCS1) of the pD vector, while A9s were cloned into MCS2. For expression and purification of A8/A9 heterocomplexes (A8/A9s), pD plasmids containing an A8 gene in MCS1 and an A9 gene in MCS2 were used as previously described (<xref ref-type="bibr" rid="bib26">Futami et al., 2016</xref>). Opossum A8 was sub-cloned into an MBP-LIC vector to yield a His-MBP-TEV-opA8 construct. For opossum A8/A9, the entire His-MBP-TEV-A8 construct was then sub-cloned into MCS1 of a pD vector containing a marsupial A9 in MCS2. Other S100s (A1, A5, A7, A11, A14, and P) were previously cloned into a pET28/30 vector to yield a TEV-cleavable N-terminal His tag (<xref ref-type="bibr" rid="bib94">Wheeler et al., 2016</xref>). Cysteine-free versions of all S100 genes, as well as point mutants, were prepared using site-directed mutagenesis (Agilent).</p></sec><sec id="s4-3"><title>Protein expression and purification</title><p>Recombinant protein overexpression was conducted in <italic>E. coli</italic> BL21 (DE3) pLysS Rosetta cells. Cultures were innoculated in luria broth overnight at 37°C, shaking at 250 rpm, in the presence of ampicillin and chloramphenicol. The following day, 10 ml of saturated culture was diluted into 1.5 L of media with antibiotics, grown to OD<sub>600</sub> = 0.6–1, and then induced overnight at 16°C using 1 mM IPTG. Cells were pelleted at 3,000 rpm for 20 min and stored at −20°C for no more than three months.</p><p>Lysates were prepared by vortexing pellets (3–5 g) in tris buffer (25 mM tris, 100 mM NaCl, pH 7.4) and incubating for 20 min at RT with DNAse I and lysozyme (ThermoFisher Scientific). Lysates were sonicated and cell debris was pelleted by centrifugation at 15,000 rpm at 4°C for &gt;20 min. All proteins were purified on an Äkta PrimePlus FPLC using various 5 ml HiTrap columns (HisTrap FF (Ni-affinity), Q HP (anion exchange), SP FF (cation exchange), and MBPTrap HP (MBP) - GE Health Science). A1, A5, A7, A11, A14, and S100P were purified using a a TEV-cleavable His tag strategy used by our lab previously (<xref ref-type="bibr" rid="bib59">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Postel et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Gudmundsson and Agerberth, 1999</xref>). All other S100s, except for opossum A8 and opossum A8/A9, were purified in three steps using Ni-affinity chromatography in the presence of calcium followed by two rounds of anion exchange chromatography at different pHs. For Ni-affinity chromatography, proteins were eluted over a 50 ml gradient from 25 to 1000 mM imidazole in tris buffer. Peak elution fractions were pooled and placed in dialysis overnight at 4°C in 4 L of tris buffer (calcium-free) adjusted to pH 8. Anion exchange chromatography was then performed the following day over a 50 ml gradient from 100 to 1000 mM NaCl in pH eight tris buffer. Fractions containing majority S100 were pooled and analyzed for purity on an SDS-PAGE gel. If trace contaminants remained, an additional anion exchange step was performed at pH six using the same elution strategy as for the previous anion exchange step.</p><p>Opossum A8 and A8/A9 lysates were prepared as above and then flowed over a nickel column, eluting over a 50 ml gradient from 25 to 1000 mM imidazole in tris buffer. Peak elution was pooled and the MBP tag was cleaved by incubation with ~1:5 TEV protease at 4°C overnight in 4 L of tris buffer. The MBP tag was then removed by flowing the sample over an MBPTrap column, step-eluting with 10 mM maltose. Additional MBP columns were run until all MBP was removed from the purified protein, assessed by SDS-PAGE. If necessary, an additional anion exchange step at pH eight was performed to complete purification. All purified proteins were dialyzed overnight at 4°C in tris buffer + 2 g/L Chelex-100 resin (Biorad), flash-frozen the following day in liquid nitrogen, and stored at −80°C.</p></sec><sec id="s4-4"><title>Biophysical and biochemical characterization</title><p>For all experiments, protein aliquots were thawed fresh from freezer stocks and were either dialyzed in the appropriate experimental buffer overnight at 4°C or exchanged 3X into experimental buffer using 3K microsep spin concentrator columns (Pall Corporation). All samples were filter-sterilized using 0.1 µm spin filters (EMD Millipore) prior to measuring concentration and using in experiments. Thawed aliquots were used for no more than one week before discarding. All concentrations were measured by Bradford assay and correspond to micromolar dimeric protein.</p><p>For in vitro proteolytic susceptibility experiments, proteins were dialyzed or exchanged into tris buffer + 1 mM CaCl<sub>2</sub>. 12.5 µM S100 protein was treated with 5 µM monomeric Proteinase K from <italic>Tritirachium album</italic> (Sigma Aldrich), cathepsin G from human neutrophils (Athens Research), or neutrophil elastase from human neutrophils (Millipore Sigma) in thin-walled PCR tubes, which were held at a constant temperature of 25°C over the course of the experiment using a thermal cycler. Proteinase K activity was quenched at different time points by directly pipetting an aliquot of the reaction into an equal volume of 95% Laemmli SDS-PAGE loading buffer + 5% BME at 95°C in a separate thermal cycler. Time points were analyzed via SDS-PAGE, and gels were quantified by densitometry using in-house gel analysis software (<ext-link ext-link-type="uri" xlink:href="https://github.com/harmslab/gelquant">https://github.com/harmslab/gelquant</ext-link>, v1.0; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/gelquant">https://github.com/elifesciences-publications/gelquant</ext-link>; <xref ref-type="bibr" rid="bib36">Harman, 2020</xref>). An exponential decay function (<inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>) was fit to the data to extract the decay rate, floating <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf3"><mml:mi>k</mml:mi><mml:mo>.</mml:mo></mml:math></inline-formula> Standard deviations were calculated from fits by taking the square root of the diagonalized covariance matrix and by error propagation.</p><p>Oligomeric states were measured using a superose 12 10/300 GL size exclusion column (Amersham Biosciences) with in-line concentration detection using refractive index (RI) and particle mass measured using a multiangle laser light scattering (MALS) instrument (Dawn Heleos, Wyatt Technology). Samples were concentrated to 0.5–2 mg/ml in tris buffer + 0.5 mM CaCl<sub>2</sub>, 0.1 µm sterile-filtered, and analyzed at a flow rate of 0.2 ml/min. Data were processed using manufacturer’s software (Astra).</p><p>Circular dichroism (CD) and chemical denaturation experiments were performed using a Jasco J-815 CD spectrometer and spectroscopy-grade guanidine hydrochloride (gdn-HCl) or urea. Chemical denaturation was performed using 25 µM dimeric protein in tris buffer with CaCl<sub>2</sub>, with tris substituted for spectroscopy-grade trizma. Reversible unfolding and refolding curves were constructed by making concentrated 100 µM protein stocks in either buffer or 6M gdm or 10M urea and then preparing protein dilutions in various concentrations of gdn-HCl or urea in buffer. Samples were left to equilibrate in denaturant between three hours and overnight to allow for equilibration and were then analyzed by CD. Unfolding/refolding equilibration was confirmed by comparing unfolded vs. refolded protein at the same concentration. CD signal was quantified at 222 nm in a 1 mm cuvette using a 1 nm bandwidth, standard sensitivity, and 2 s D.I.T. HT voltage was &lt;600 V. We fit a two-state unfolding model:<disp-formula id="equ1"><mml:math id="m1"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub> <mml:mi/><mml:msub><mml:mrow><mml:mo>+</mml:mo> <mml:mi/><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mi>x</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow> <mml:mi/><mml:mo>+</mml:mo> <mml:mi/><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mi>x</mml:mi><mml:mo>)</mml:mo><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo> <mml:mi/><mml:mfrac><mml:mrow><mml:mo>∆</mml:mo><mml:mi>G</mml:mi><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn> <mml:mi/><mml:mo>+</mml:mo> <mml:mi/><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo> <mml:mi/><mml:mfrac><mml:mrow><mml:mo>∆</mml:mo><mml:mi>G</mml:mi><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:msup> <mml:mi/> <mml:mi/></mml:mrow></mml:mfrac></mml:math></disp-formula>to the data to extract thermodynamic parameters, where <inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo> <mml:mi/><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></inline-formula><inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo> <mml:mi/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi> <mml:mi/><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> are the folded and unfolded baseline y-intercepts and slopes, <inline-formula><mml:math id="inf6"><mml:mo>∆</mml:mo><mml:mi>G</mml:mi></mml:math></inline-formula> is the unfolding free energy, <inline-formula><mml:math id="inf7"><mml:mi>m</mml:mi></mml:math></inline-formula> is the m-value, <italic>R =</italic> 0.001987 J⋅K<sup>−1</sup>mol<sup>−1</sup> and <italic>T =</italic> 298.15 K. Standard deviations were calculated from fits by taking the square root of the diagonalized covariance matrix and by error propagation. Apparent unfolding kinetics studies were performed using the above conditions by spiking concentrated protein stock directly into 6M gdm and immediately monitoring CD signal at 222 nm.</p></sec><sec id="s4-5"><title>Cell lines</title><p>We purchased commercially distributed HEK293T cells from ATCC (CRL-11268). Because we are using this cell line as a host for heterologous transient transfections, the appropriate control for consistency between assays is the measurement of reporter output for a set of control plasmids and a panel of known treatments. Upon thawing each batch of cells, we run a positive control for ligand-induced response. We transfect the cells with plasmids encoding human CD14, human MD-2, human TLR4, renilla luciferase behind a constitutive promoter, and firefly luciferase behind an NF-KB promoter. We then characterize the raw luciferase output for five treatments: 1) mock, 2) LPS, 3) LPS + polymyxin B, 4) S100A9 + polymyxin B, and 5) S100A9 + 1.25x polymyxin B. This has a stereotypical pattern of responses in renilla luciferase (high for all) and firefly luciferase (low, high, low, high, high). To validate that this response is dependent on the transfected TLR4 complex as opposed to the cells themselves, we repeat the experiment but exclude the TLR4 plasmid. This should give identical renilla luciferase values but no firefly luciferase output in response to any treatment. To ensure that the cells maintain their properties between passages, we repeat the mock, LPS, and LPS + polymyxin B control on every single experimental plate. This assay has a built-in control for mycoplasma contamination: high firefly luciferase signal in the absence of added agonist. This indicates that there is another source of TLR4-induced NF-kappa B output in the cells—most plausibly, contamination. This mycoplasma sensing approach is used in the commercially available HEK-BLUE mycoplasma detection kit (Invivogen). We discard any cells that exhibit high background values or reach 30 passages.</p></sec><sec id="s4-6"><title>Functional assays</title><p>The antimicrobial activity of S100s was measured against <italic>S. epidermidis</italic> using a well-established assay (<xref ref-type="bibr" rid="bib34">Hadley et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Nakashige et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Brunjes Brophy et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Brophy et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Cunden et al., 2016</xref>). The day before, a 5 ml starter culture of <italic>S. epidermidis</italic> in tryptic soy broth (TSB) was grown overnight. The next day, the culture was diluted ~1:100 in TSB and grown for approximately 2 hr to an OD600 of ~0.8. Immediately prior to experiment, the <italic>S. epidermidis</italic> culture was again diluted 1:100 at a ratio of 62:38 experimental buffer (25 mM tris, 100 mM NaCl, 3 mM CaCl<sub>2</sub>, pH 7.4):TSB. S100 proteins were exchanged into experimental buffer. Each well of a sterile 96-well plate was prepared with 40 µl of <italic>S. epidermidis</italic> diluted in experimental buffer + TSB, S100 protein at the desired concentration in experimental buffer, and then filled to 200 µl, maintaining a ratio of 62:38 experimental buffer:TB. <italic>S. epidermidis</italic> growth was monitored on a plate reader, measuring OD600 every 15 min for 13 hr. Each measurement was collected in technical triplicate and background-subtracted using a blank containing experimental buffer and TSB alone. Protein samples were confirmed to lack bacterial contamination by measuring S100 protein growth in experimental buffer and TSB lacking <italic>S. epidermidis.</italic></p><p>All plasmids, cell culture conditions, and transfections for measuring the activity of S100s against TLR4s were identical to those previously described (<xref ref-type="bibr" rid="bib64">Nakashige et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Loes et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Anderson et al., 2019</xref>). Briefly, human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were maintained up to 30 passages in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Lipopolysaccharide <italic>E. coli</italic> K-12 LPS (LPS - tlrl-eklps, Invivogen) aliquots were prepared at 5 mg/ml in endotoxin-free water and stored at −20°C. Working solutions were prepared at 10 ug/ml and stored at 4°C to avoid freeze-thaw cycles. S100 proteins were prepared by exchanging into endotoxin-free PBS and incubating with an endotoxin removal column (Thermo Fisher Scientific) for 2 hr. S100 LPS contamination was assessed by measuring activity with and without Polymyxin B, an LPS chelating agent (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). LPS (200 ng per 100 µl well) or S100 (0.8, 0.4, 2, 4, or 5 µM dimer) treatments were prepared by diluting in 25:75 endotoxin-free PBS:serum-free Dulbecco’s Modified Eagle Media (DMEM – Thermo Fisher Scientific). Polymyxin B (PB, 200 µg per 100 µl well) was added to all S100 experimental samples to limit background endotoxin contamination activity from recombinant protein preps. Cells were incubated with treatments for 3 hr prior to assaying activity. The Dual-Glo Luciferase Assay System (Promega) was used to assay Firefly and Renilla luciferase activity of individual wells. Each NF-κB induction value shown represents the Firefly luciferase activity divided by the Renilla luciferase activity, background-subtracted using the LPS + PB activity for each TLR4 species and normalized to the activity of LPS alone for each TLR4 species to normalize between plates. All measurements were performed using three technical replicates per plate, a minimum of three biological replicates total, and a minimum of two separate protein preps.</p><p>For TLR4 activation measurements by A9 proteolytic products, 12.5 µM hA9 or hA9 M63F were incubated with 2.5 mg/ml Proteinase K immobilized to agarose at 37°C for increasing amounts of time. The reaction was quenched by spin-filtering the sample to remove Proteinase K. 2 µM A9 proteolysis treatments were then added to cells as outlined above. Western blots were performed by running an SDS-PAGE gel and transferring to a nitrocellulose membrane. Membranes were blocked using Odyssey Blocking Buffer for 1 hr, incubated with 1:1000 mouse anti-S100A9 primary antibody (M13 clone 1CD22, Abnova) for 1 hr, and incubated with 1:10,000 IRDye Goat anti-mouse 800CW IgG (H+L, Licor) for 1 hr, with 3 × 5 min TBST washes in between each step. Blots were imaged using the Licor Odyssey Fc imaging system.</p></sec><sec id="s4-7"><title>Species cartoons</title><p>All species cartoons were taken from the following websites: <ext-link ext-link-type="uri" xlink:href="http://phylopic.org/image/c089caae-43ef-4e4e-bf26-973dd4cb65c5/">http://phylopic.org/image/c089caae-43ef-4e4e-bf26-973dd4cb65c5/</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://phylopic.org/image/aff847b0-ecbd-4d41-98ce-665921a6d96e/">http://phylopic.org/image/aff847b0-ecbd-4d41-98ce-665921a6d96e/</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://phylopic.org/image/0f6af3d8-49d2-4d75-8edf-08598387afde/">http://phylopic.org/image/0f6af3d8-49d2-4d75-8edf-08598387afde/</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://phylopic.org/image/dde4f926-c04c-47ef-a337-927ceb36e7ef/">http://phylopic.org/image/dde4f926-c04c-47ef-a337-927ceb36e7ef/</ext-link>. We acknowledge Sarah Werning and David Liao as authors of the opossum and mouse cartoons respectively, which were made publicly available through the creative commons attributions 3.0 unported license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</ext-link>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank current and former members of the Harms lab for helpful discussion and input. We thank the Barber lab for use of their cell culture facility. We thank Karen Guillemin for helpful comments on the manuscript.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Visualization, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Alignment of modern and ancestrally reconstructed S100 proteins used in this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-54100-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Species-corrected tree used for ancestral sequence reconstruction.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-54100-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-54100-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>JA</given-names></name><name><surname>Loes</surname> <given-names>AN</given-names></name><name><surname>Waddell</surname> <given-names>GL</given-names></name><name><surname>Harms</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tracing the evolution of novel features of human toll‐like receptor 4</article-title><source>Protein Science : A Publication of the Protein Society</source><volume>28</volume><fpage>1350</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1002/pro.3644</pub-id><pub-id pub-id-type="pmid">31075178</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auvynet</surname> <given-names>C</given-names></name><name><surname>Rosenstein</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity: amps, the small yet big players of immunity</article-title><source>The FEBS Journal</source><volume>276</volume><fpage>6497</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07360.x</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Averill</surname> <given-names>MM</given-names></name><name><surname>Kerkhoff</surname> <given-names>C</given-names></name><name><surname>Bornfeldt</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>S100A8 and S100A9 in cardiovascular biology and disease</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>32</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.111.236927</pub-id><pub-id pub-id-type="pmid">22095980</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname> <given-names>TM</given-names></name><name><surname>Nakashige</surname> <given-names>TG</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name><name><surname>Neidig</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Magnetic circular dichroism studies of iron(ii) binding to human calprotectin</article-title><source>Chemical Science</source><volume>8</volume><fpage>1369</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1039/c6sc03487j</pub-id><pub-id pub-id-type="pmid">28451278</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bals</surname> <given-names>R</given-names></name><name><surname>Wilson</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cathelicidins--a family of multifunctional antimicrobial peptides</article-title><source>Cellular and Molecular Life Sciences</source><volume>60</volume><fpage>711</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1007/s00018-003-2186-9</pub-id><pub-id pub-id-type="pmid">12785718</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berntzen</surname> <given-names>HB</given-names></name><name><surname>Fagerhol</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>L1, a major granulocyte protein; isolation of high quantities of its subunits</article-title><source>Scandinavian Journal of Clinical and Laboratory Investigation</source><volume>50</volume><fpage>769</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1080/00365519009091071</pub-id><pub-id pub-id-type="pmid">2293338</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besold</surname> <given-names>AN</given-names></name><name><surname>Culbertson</surname> <given-names>EM</given-names></name><name><surname>Nam</surname> <given-names>L</given-names></name><name><surname>Hobbs</surname> <given-names>RP</given-names></name><name><surname>Boyko</surname> <given-names>A</given-names></name><name><surname>Maxwell</surname> <given-names>CN</given-names></name><name><surname>Chazin</surname> <given-names>WJ</given-names></name><name><surname>Marques</surname> <given-names>AR</given-names></name><name><surname>Culotta</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Antimicrobial action of calprotectin that does not involve metal withholding</article-title><source>Metallomics</source><volume>10</volume><fpage>1728</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1039/C8MT00133B</pub-id><pub-id pub-id-type="pmid">30206620</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besold</surname> <given-names>AN</given-names></name><name><surname>Gilston</surname> <given-names>BA</given-names></name><name><surname>Radin</surname> <given-names>JN</given-names></name><name><surname>Ramsoomair</surname> <given-names>C</given-names></name><name><surname>Culbertson</surname> <given-names>EM</given-names></name><name><surname>Li</surname> <given-names>CX</given-names></name><name><surname>Cormack</surname> <given-names>BP</given-names></name><name><surname>Chazin</surname> <given-names>WJ</given-names></name><name><surname>Kehl-Fie</surname> <given-names>TE</given-names></name><name><surname>Culotta</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Role of calprotectin in withholding zinc and copper from candida albicans</article-title><source>Infection and Immunity</source><volume>86</volume><elocation-id>e00779</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00779-17</pub-id><pub-id pub-id-type="pmid">29133349</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>DAMPs, PAMPs and alarmins: all we need to know about danger</article-title><source>Journal of Leukocyte Biology</source><volume>81</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1189/jlb.0306164</pub-id><pub-id pub-id-type="pmid">17032697</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Björk</surname> <given-names>P</given-names></name><name><surname>Björk</surname> <given-names>A</given-names></name><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Stenström</surname> <given-names>M</given-names></name><name><surname>Liberg</surname> <given-names>D</given-names></name><name><surname>Olsson</surname> <given-names>A</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name><name><surname>Ivars</surname> <given-names>F</given-names></name><name><surname>Leanderson</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to Quinoline-3-Carboxamides</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e1000097</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000097</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bomblies</surname> <given-names>K</given-names></name><name><surname>Doebley</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pleiotropic effects of the duplicate maize <italic>FLORICAULA/LEAFY</italic> genes <italic>zfl1</italic> and <italic>zfl2</italic> on traits under selection during maize domestication</article-title><source>Genetics</source><volume>172</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1534/genetics.105.048595</pub-id><pub-id pub-id-type="pmid">16204211</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozzi</surname> <given-names>AT</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Avian MRP126 restricts microbial growth through ca(II)-Dependent zn(II) Sequestration</article-title><source>Biochemistry</source><volume>59</volume><fpage>802</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.9b01012</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brophy</surname> <given-names>MB</given-names></name><name><surname>Hayden</surname> <given-names>JA</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin</article-title><source>Journal of the American Chemical Society</source><volume>134</volume><fpage>18089</fpage><lpage>18100</lpage><pub-id pub-id-type="doi">10.1021/ja307974e</pub-id><pub-id pub-id-type="pmid">23082970</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunjes Brophy</surname> <given-names>M</given-names></name><name><surname>Nakashige</surname> <given-names>TG</given-names></name><name><surname>Gaillard</surname> <given-names>A</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Contributions of the S100A9 C-Terminal tail to High-Affinity mn(II) Chelation by the Host-Defense protein human calprotectin</article-title><source>Journal of the American Chemical Society</source><volume>135</volume><fpage>17804</fpage><lpage>17817</lpage><pub-id pub-id-type="doi">10.1021/ja407147d</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Miller</surname> <given-names>AL</given-names></name><name><surname>Rebelatto</surname> <given-names>M</given-names></name><name><surname>Brewah</surname> <given-names>Y</given-names></name><name><surname>Rowe</surname> <given-names>DC</given-names></name><name><surname>Clarke</surname> <given-names>L</given-names></name><name><surname>Czapiga</surname> <given-names>M</given-names></name><name><surname>Rosenthal</surname> <given-names>K</given-names></name><name><surname>Imamichi</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>CS</given-names></name><name><surname>Chowdhury</surname> <given-names>PS</given-names></name><name><surname>Naiman</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Humbles</surname> <given-names>AA</given-names></name><name><surname>Herbst</surname> <given-names>R</given-names></name><name><surname>Sims</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0115828</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0115828</pub-id><pub-id pub-id-type="pmid">25706559</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>HL</given-names></name><name><surname>Jhingran</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Vareechon</surname> <given-names>C</given-names></name><name><surname>de Jesus Carrion</surname> <given-names>S</given-names></name><name><surname>Skaar</surname> <given-names>EP</given-names></name><name><surname>Chazin</surname> <given-names>WJ</given-names></name><name><surname>Calera</surname> <given-names>JA</given-names></name><name><surname>Hohl</surname> <given-names>TM</given-names></name><name><surname>Pearlman</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Zinc and manganese chelation by neutrophil S100A8/A9 (Calprotectin) Limits extracellular <italic>Aspergillus fumigatus</italic> Hyphal Growth and Corneal Infection</article-title><source>The Journal of Immunology</source><volume>196</volume><fpage>336</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502037</pub-id><pub-id pub-id-type="pmid">26582948</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunden</surname> <given-names>LS</given-names></name><name><surname>Gaillard</surname> <given-names>A</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Calcium ions tune the Zinc-Sequestering properties and antimicrobial activity of human S100A12</article-title><source>Chemical Science</source><volume>7</volume><fpage>1338</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1039/C5SC03655K</pub-id><pub-id pub-id-type="pmid">26913170</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunden</surname> <given-names>LS</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bioinorganic explorations of zn(II) Sequestration by human S100 Host-Defense proteins</article-title><source>Biochemistry</source><volume>57</volume><fpage>1673</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.7b01305</pub-id><pub-id pub-id-type="pmid">29381858</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damo</surname> <given-names>SM</given-names></name><name><surname>Kehl-Fie</surname> <given-names>TE</given-names></name><name><surname>Sugitani</surname> <given-names>N</given-names></name><name><surname>Holt</surname> <given-names>ME</given-names></name><name><surname>Rathi</surname> <given-names>S</given-names></name><name><surname>Murphy</surname> <given-names>WJ</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Betz</surname> <given-names>C</given-names></name><name><surname>Hench</surname> <given-names>L</given-names></name><name><surname>Fritz</surname> <given-names>G</given-names></name><name><surname>Skaar</surname> <given-names>EP</given-names></name><name><surname>Chazin</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens</article-title><source>PNAS</source><volume>110</volume><fpage>3841</fpage><lpage>3846</lpage><pub-id pub-id-type="doi">10.1073/pnas.1220341110</pub-id><pub-id pub-id-type="pmid">23431180</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>You</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HBx-induced S100A9 in NF-κB dependent manner promotes growth and metastasis of hepatocellular carcinoma cells</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>629</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0512-2</pub-id><pub-id pub-id-type="pmid">29795379</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrchen</surname> <given-names>JM</given-names></name><name><surname>Sunderkötter</surname> <given-names>C</given-names></name><name><surname>Foell</surname> <given-names>D</given-names></name><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and Cancer</article-title><source>Journal of Leukocyte Biology</source><volume>86</volume><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1189/jlb.1008647</pub-id><pub-id pub-id-type="pmid">19451397</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrhardt</surname> <given-names>C</given-names></name><name><surname>Schmolke</surname> <given-names>M</given-names></name><name><surname>Matzke</surname> <given-names>A</given-names></name><name><surname>Knoblauch</surname> <given-names>A</given-names></name><name><surname>Will</surname> <given-names>C</given-names></name><name><surname>Wixler</surname> <given-names>V</given-names></name><name><surname>Ludwig</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Polyethylenimine, a cost-effective transfection reagent</article-title><source>Signal Transduction</source><volume>6</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1002/sita.200500073</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eick</surname> <given-names>GN</given-names></name><name><surname>Bridgham</surname> <given-names>JT</given-names></name><name><surname>Anderson</surname> <given-names>DP</given-names></name><name><surname>Harms</surname> <given-names>MJ</given-names></name><name><surname>Thornton</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Robustness of reconstructed ancestral protein functions to statistical uncertainty</article-title><source>Molecular Biology and Evolution</source><volume>34</volume><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1093/molbev/msw223</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname> <given-names>A</given-names></name><name><surname>Polverino de Laureto</surname> <given-names>P</given-names></name><name><surname>De Filippis</surname> <given-names>V</given-names></name><name><surname>Scaramella</surname> <given-names>E</given-names></name><name><surname>Zambonin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Probing the partly folded states of proteins by limited proteolysis</article-title><source>Folding and Design</source><volume>2</volume><fpage>R17</fpage><lpage>R26</lpage><pub-id pub-id-type="doi">10.1016/S1359-0278(97)00010-2</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>Z</given-names></name><name><surname>Thorpe</surname> <given-names>M</given-names></name><name><surname>Akula</surname> <given-names>S</given-names></name><name><surname>Chahal</surname> <given-names>G</given-names></name><name><surname>Hellman</surname> <given-names>LT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Extended Cleavage Specificity of Human Neutrophil Elastase, Human Proteinase 3, and Their Distant Ortholog Clawed Frog PR3—Three Elastases With Similar Primary but Different Extended Specificities and Stability</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2387</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02387</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futami</surname> <given-names>J</given-names></name><name><surname>Atago</surname> <given-names>Y</given-names></name><name><surname>Azuma</surname> <given-names>A</given-names></name><name><surname>Putranto</surname> <given-names>EW</given-names></name><name><surname>Kinoshita</surname> <given-names>R</given-names></name><name><surname>Murata</surname> <given-names>H</given-names></name><name><surname>Sakaguchi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An efficient method for the preparation of preferentially heterodimerized recombinant S100A8/A9 coexpressed in Escherichia coli</article-title><source>Biochemistry and Biophysics Reports</source><volume>6</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.bbrep.2016.03.009</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname> <given-names>DM</given-names></name><name><surname>Brophy</surname> <given-names>MB</given-names></name><name><surname>Bowman</surname> <given-names>SEJ</given-names></name><name><surname>Stich</surname> <given-names>TA</given-names></name><name><surname>Drennan</surname> <given-names>CL</given-names></name><name><surname>Britt</surname> <given-names>RD</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Manganese Binding Properties of Human Calprotectin under Conditions of High and Low Calcium: X-ray Crystallographic and Advanced Electron Paramagnetic Resonance Spectroscopic Analysis</article-title><source>Journal of the American Chemical Society</source><volume>137</volume><fpage>3004</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.1021/ja512204s</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>L</given-names></name><name><surname>Hou</surname> <given-names>J</given-names></name><name><surname>Meng</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>S100A9-induced release of interleukin (IL)-6 and IL-8 through toll-like receptor 4 (TLR4) in human periodontal ligament cells</article-title><source>Molecular Immunology</source><volume>67</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2015.05.014</pub-id><pub-id pub-id-type="pmid">26038301</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname> <given-names>AD</given-names></name><name><surname>Nowis</surname> <given-names>D</given-names></name><name><surname>Golab</surname> <given-names>J</given-names></name><name><surname>Vandenabeele</surname> <given-names>P</given-names></name><name><surname>Krysko</surname> <given-names>DV</given-names></name><name><surname>Agostinis</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation</article-title><source>Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1805</volume><fpage>53</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2009.08.003</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruden</surname> <given-names>MA</given-names></name><name><surname>Davydova</surname> <given-names>TV</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Narkevich</surname> <given-names>VB</given-names></name><name><surname>Fomina</surname> <given-names>VG</given-names></name><name><surname>Kudrin</surname> <given-names>VS</given-names></name><name><surname>Morozova-Roche</surname> <given-names>LA</given-names></name><name><surname>Sewell</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The misfolded pro-inflammatory protein S100A9 disrupts memory via neurochemical remodelling instigating an alzheimer's disease-like cognitive deficit</article-title><source>Behavioural Brain Research</source><volume>306</volume><fpage>106</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2016.03.016</pub-id><pub-id pub-id-type="pmid">26965570</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsson</surname> <given-names>GH</given-names></name><name><surname>Agerberth</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system</article-title><source>Journal of Immunological Methods</source><volume>232</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(99)00152-0</pub-id><pub-id pub-id-type="pmid">10618508</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guharoy</surname> <given-names>M</given-names></name><name><surname>Bhowmick</surname> <given-names>P</given-names></name><name><surname>Tompa</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Design principles involving protein disorder facilitate specific substrate selection and degradation by the Ubiquitin-Proteasome system</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>6723</fpage><lpage>6731</lpage><pub-id pub-id-type="doi">10.1074/jbc.R115.692665</pub-id><pub-id pub-id-type="pmid">26851277</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guindon</surname> <given-names>S</given-names></name><name><surname>Dufayard</surname> <given-names>JF</given-names></name><name><surname>Lefort</surname> <given-names>V</given-names></name><name><surname>Anisimova</surname> <given-names>M</given-names></name><name><surname>Hordijk</surname> <given-names>W</given-names></name><name><surname>Gascuel</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0</article-title><source>Systematic Biology</source><volume>59</volume><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/sysbio/syq010</pub-id><pub-id pub-id-type="pmid">20525638</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadley</surname> <given-names>RC</given-names></name><name><surname>Gu</surname> <given-names>Y</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Initial biochemical and functional evaluation of murine calprotectin reveals ca(II)-Dependence and its ability to chelate multiple nutrient transition metal ions</article-title><source>Biochemistry</source><volume>57</volume><fpage>2846</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00309</pub-id><pub-id pub-id-type="pmid">29659256</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname> <given-names>A</given-names></name><name><surname>Sakamoto</surname> <given-names>N</given-names></name><name><surname>Ishimatsu</surname> <given-names>Y</given-names></name><name><surname>Kakugawa</surname> <given-names>T</given-names></name><name><surname>Nakashima</surname> <given-names>S</given-names></name><name><surname>Hara</surname> <given-names>S</given-names></name><name><surname>Adachi</surname> <given-names>M</given-names></name><name><surname>Fujita</surname> <given-names>H</given-names></name><name><surname>Mukae</surname> <given-names>H</given-names></name><name><surname>Kohno</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis</article-title><source>Respiratory Medicine</source><volume>106</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2011.12.010</pub-id><pub-id pub-id-type="pmid">22209187</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Harman</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Simple SDS-PAGE/western blot gel quantification software</data-title><source>GitHub</source><version designator="28c2984">28c2984</version><ext-link ext-link-type="uri" xlink:href="https://github.com/harmslab/gelquant">https://github.com/harmslab/gelquant</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname> <given-names>JA</given-names></name><name><surname>Brophy</surname> <given-names>MB</given-names></name><name><surname>Cunden</surname> <given-names>LS</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-affinity manganese coordination by human calprotectin is calcium-dependent and requires the histidine-rich site formed at the dimer interface</article-title><source>Journal of the American Chemical Society</source><volume>135</volume><fpage>775</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1021/ja3096416</pub-id><pub-id pub-id-type="pmid">23276281</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>Z</given-names></name><name><surname>Riva</surname> <given-names>M</given-names></name><name><surname>Björk</surname> <given-names>P</given-names></name><name><surname>Swärd</surname> <given-names>K</given-names></name><name><surname>Mörgelin</surname> <given-names>M</given-names></name><name><surname>Leanderson</surname> <given-names>T</given-names></name><name><surname>Ivars</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD14 is a Co-Receptor for TLR4 in the S100A9-Induced Pro-Inflammatory response in monocytes</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0156377</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0156377</pub-id><pub-id pub-id-type="pmid">27228163</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Toward a molecular understanding of pleiotropy</article-title><source>Genetics</source><volume>173</volume><fpage>1885</fpage><lpage>1891</lpage><pub-id pub-id-type="doi">10.1534/genetics.106.060269</pub-id><pub-id pub-id-type="pmid">16702416</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname> <given-names>CM</given-names></name><name><surname>Sullivan</surname> <given-names>GP</given-names></name><name><surname>Clancy</surname> <given-names>DM</given-names></name><name><surname>Afonina</surname> <given-names>IS</given-names></name><name><surname>Kulms</surname> <given-names>D</given-names></name><name><surname>Martin</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neutrophil-Derived proteases escalate inflammation through activation of IL-36 family cytokines</article-title><source>Cell Reports</source><volume>14</volume><fpage>708</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.072</pub-id><pub-id pub-id-type="pmid">26776523</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heutinck</surname> <given-names>KM</given-names></name><name><surname>ten Berge</surname> <given-names>IJ</given-names></name><name><surname>Hack</surname> <given-names>CE</given-names></name><name><surname>Hamann</surname> <given-names>J</given-names></name><name><surname>Rowshani</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Serine proteases of the human immune system in health and disease</article-title><source>Molecular Immunology</source><volume>47</volume><fpage>1943</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2010.04.020</pub-id><pub-id pub-id-type="pmid">20537709</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular basis underlying functional pleiotropy of cytokines and growth factors</article-title><source>Biochemical and Biophysical Research Communications</source><volume>260</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.0609</pub-id><pub-id pub-id-type="pmid">10403765</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>I</given-names></name><name><surname>Jia</surname> <given-names>X</given-names></name><name><surname>Johansson</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Moskalenko</surname> <given-names>R</given-names></name><name><surname>Steinau</surname> <given-names>A</given-names></name><name><surname>Forsgren</surname> <given-names>L</given-names></name><name><surname>Wågberg</surname> <given-names>T</given-names></name><name><surname>Svensson</surname> <given-names>J</given-names></name><name><surname>Zetterberg</surname> <given-names>H</given-names></name><name><surname>Morozova-Roche</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer’s Disease</article-title><source>ACS Chemical Neuroscience</source><volume>7</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.5b00265</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>CH</given-names></name><name><surname>Kuo</surname> <given-names>CJ</given-names></name><name><surname>Liang</surname> <given-names>SS</given-names></name><name><surname>Chi</surname> <given-names>SW</given-names></name><name><surname>Hsi</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>CC</given-names></name><name><surname>Lee</surname> <given-names>KT</given-names></name><name><surname>Chiou</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma</article-title><source>BBA Clinical</source><volume>3</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.bbacli.2015.02.004</pub-id><pub-id pub-id-type="pmid">26675302</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The structural aspects of limited proteolysis of native proteins</article-title><source>Biochimica Et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology</source><volume>1382</volume><fpage>191</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S0167-4838(97)00175-1</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname> <given-names>ZA</given-names></name><name><surname>Armour</surname> <given-names>CL</given-names></name><name><surname>Phipps</surname> <given-names>S</given-names></name><name><surname>Sukkar</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RAGE and TLRs: relatives, friends or Neighbours?</article-title><source>Molecular Immunology</source><volume>56</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2013.07.008</pub-id><pub-id pub-id-type="pmid">23954397</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imoto</surname> <given-names>T</given-names></name><name><surname>Yamada</surname> <given-names>H</given-names></name><name><surname>Ueda</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Unfolding rates of globular proteins determined by kinetics of proteolysis</article-title><source>Journal of Molecular Biology</source><volume>190</volume><fpage>647</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(86)90250-0</pub-id><pub-id pub-id-type="pmid">3783715</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itou</surname> <given-names>H</given-names></name><name><surname>Yao</surname> <given-names>M</given-names></name><name><surname>Fujita</surname> <given-names>I</given-names></name><name><surname>Watanabe</surname> <given-names>N</given-names></name><name><surname>Suzuki</surname> <given-names>M</given-names></name><name><surname>Nishihira</surname> <given-names>J</given-names></name><name><surname>Tanaka</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The crystal structure of human MRP14 (S100A9), a ca(2+)-dependent regulator protein in inflammatory process</article-title><source>Journal of Molecular Biology</source><volume>316</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2001.5340</pub-id><pub-id pub-id-type="pmid">11851337</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janoff</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Neutrophil proteases in inflammation</article-title><source>Annual Review of Medicine</source><volume>23</volume><fpage>177</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1146/annurev.me.23.020172.001141</pub-id><pub-id pub-id-type="pmid">4345523</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerke</surname> <given-names>U</given-names></name><name><surname>Hernandez</surname> <given-names>DP</given-names></name><name><surname>Beaudette</surname> <given-names>P</given-names></name><name><surname>Korkmaz</surname> <given-names>B</given-names></name><name><surname>Dittmar</surname> <given-names>G</given-names></name><name><surname>Kettritz</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutrophil serine proteases exert proteolytic activity on endothelial cells</article-title><source>Kidney International</source><volume>88</volume><fpage>764</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/ki.2015.159</pub-id><pub-id pub-id-type="pmid">26061547</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>DT</given-names></name><name><surname>Taylor</surname> <given-names>WR</given-names></name><name><surname>Thornton</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The rapid generation of mutation data matrices from protein sequences</article-title><source>Bioinformatics</source><volume>8</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/8.3.275</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Källberg</surname> <given-names>E</given-names></name><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Liberg</surname> <given-names>D</given-names></name><name><surname>Olsson</surname> <given-names>A</given-names></name><name><surname>Björk</surname> <given-names>P</given-names></name><name><surname>Wikström</surname> <given-names>P</given-names></name><name><surname>Bergh</surname> <given-names>A</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name><name><surname>Ivars</surname> <given-names>F</given-names></name><name><surname>Leanderson</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>S100A9 interaction with TLR4 promotes tumor growth</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e34207</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034207</pub-id><pub-id pub-id-type="pmid">22470535</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>JH</given-names></name><name><surname>Hwang</surname> <given-names>SM</given-names></name><name><surname>Chung</surname> <given-names>IY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-κB pathways</article-title><source>Immunology</source><volume>144</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/imm.12352</pub-id><pub-id pub-id-type="pmid">24975020</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessenbrock</surname> <given-names>K</given-names></name><name><surname>Dau</surname> <given-names>T</given-names></name><name><surname>Jenne</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response</article-title><source>Journal of Molecular Medicine</source><volume>89</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s00109-010-0677-3</pub-id><pub-id pub-id-type="pmid">20809089</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>Kang</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>ST</given-names></name><name><surname>Yu</surname> <given-names>MH</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of S100A8 and S100A9 as serological markers for colorectal Cancer</article-title><source>Journal of Proteome Research</source><volume>8</volume><fpage>1368</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1021/pr8007573</pub-id><pub-id pub-id-type="pmid">19186948</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laouedj</surname> <given-names>M</given-names></name><name><surname>Tardif</surname> <given-names>MR</given-names></name><name><surname>Gil</surname> <given-names>L</given-names></name><name><surname>Raquil</surname> <given-names>MA</given-names></name><name><surname>Lachhab</surname> <given-names>A</given-names></name><name><surname>Pelletier</surname> <given-names>M</given-names></name><name><surname>Tessier</surname> <given-names>PA</given-names></name><name><surname>Barabé</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>S100A9 induces differentiation of acute myeloid leukemia cells through TLR4</article-title><source>Blood</source><volume>129</volume><fpage>1980</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-738005</pub-id><pub-id pub-id-type="pmid">28137827</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leask</surname> <given-names>A</given-names></name><name><surname>Abraham</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology</article-title><source>Biochemistry and Cell Biology</source><volume>81</volume><fpage>355</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1139/o03-069</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>NR</given-names></name><name><surname>Park</surname> <given-names>BS</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Gu</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Kim</surname> <given-names>IS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cytokine secreted by S100A9 via TLR4 in monocytes delays neutrophil apoptosis by inhibition of caspase 9/3 pathway</article-title><source>Cytokine</source><volume>86</volume><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2016.07.005</pub-id><pub-id pub-id-type="pmid">27459393</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>MW</given-names></name><name><surname>Lee</surname> <given-names>EY</given-names></name><name><surname>Wong</surname> <given-names>GCL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>What can pleiotropic proteins in innate immunity teach us about bioconjugation and molecular design?</article-title><source>Bioconjugate Chemistry</source><volume>29</volume><fpage>2127</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00176</pub-id><pub-id pub-id-type="pmid">29771496</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>JZ</given-names></name><name><surname>Jellbauer</surname> <given-names>S</given-names></name><name><surname>Poe</surname> <given-names>AJ</given-names></name><name><surname>Ton</surname> <given-names>V</given-names></name><name><surname>Pesciaroli</surname> <given-names>M</given-names></name><name><surname>Kehl-Fie</surname> <given-names>TE</given-names></name><name><surname>Restrepo</surname> <given-names>NA</given-names></name><name><surname>Hosking</surname> <given-names>MP</given-names></name><name><surname>Edwards</surname> <given-names>RA</given-names></name><name><surname>Battistoni</surname> <given-names>A</given-names></name><name><surname>Pasquali</surname> <given-names>P</given-names></name><name><surname>Lane</surname> <given-names>TE</given-names></name><name><surname>Chazin</surname> <given-names>WJ</given-names></name><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name><name><surname>Skaar</surname> <given-names>EP</given-names></name><name><surname>Raffatellu</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut</article-title><source>Cell Host &amp; Microbe</source><volume>11</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.01.017</pub-id><pub-id pub-id-type="pmid">22423963</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loes</surname> <given-names>AN</given-names></name><name><surname>Bridgham</surname> <given-names>JT</given-names></name><name><surname>Harms</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Coevolution of the Toll-Like receptor 4 complex with calgranulins and lipopolysaccharide</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>304</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00304</pub-id><pub-id pub-id-type="pmid">29515592</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nacken</surname> <given-names>W</given-names></name><name><surname>Kerkhoff</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The hetero-oligomeric complex of the S100A8/S100A9 protein is extremely protease resistant</article-title><source>FEBS Letters</source><volume>581</volume><fpage>5127</fpage><lpage>5130</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2007.09.060</pub-id><pub-id pub-id-type="pmid">17936757</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Akashi</surname> <given-names>S</given-names></name><name><surname>Nagafuku</surname> <given-names>M</given-names></name><name><surname>Ogata</surname> <given-names>M</given-names></name><name><surname>Iwakura</surname> <given-names>Y</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name><name><surname>Kosugi</surname> <given-names>A</given-names></name><name><surname>Kimoto</surname> <given-names>M</given-names></name><name><surname>Miyake</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Essential role of MD-2 in LPS responsiveness and TLR4 distribution</article-title><source>Nature Immunology</source><volume>3</volume><fpage>667</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/ni809</pub-id><pub-id pub-id-type="pmid">12055629</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashige</surname> <given-names>TG</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Krebs</surname> <given-names>C</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human calprotectin is an iron-sequestering host-defense protein</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1891</pub-id><pub-id pub-id-type="pmid">26302479</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashige</surname> <given-names>TG</given-names></name><name><surname>Stephan</surname> <given-names>JR</given-names></name><name><surname>Cunden</surname> <given-names>LS</given-names></name><name><surname>Brophy</surname> <given-names>MB</given-names></name><name><surname>Wommack</surname> <given-names>AJ</given-names></name><name><surname>Keegan</surname> <given-names>BC</given-names></name><name><surname>Shearer</surname> <given-names>JM</given-names></name><name><surname>Nolan</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The hexahistidine motif of Host-Defense protein human calprotectin contributes to zinc withholding and its functional versatility</article-title><source>Journal of the American Chemical Society</source><volume>138</volume><fpage>12243</fpage><lpage>12251</lpage><pub-id pub-id-type="doi">10.1021/jacs.6b06845</pub-id><pub-id pub-id-type="pmid">27541598</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nisapakultorn</surname> <given-names>K</given-names></name><name><surname>Ross</surname> <given-names>KF</given-names></name><name><surname>Herzberg</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Calprotectin expression inhibits bacterial binding to mucosal epithelial cells</article-title><source>Infection and Immunity</source><volume>69</volume><fpage>3692</fpage><lpage>3696</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.6.3692-3696.2001</pub-id><pub-id pub-id-type="pmid">11349032</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donoghue</surname> <given-names>AJ</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Knudsen</surname> <given-names>GM</given-names></name><name><surname>Perera</surname> <given-names>NC</given-names></name><name><surname>Jenne</surname> <given-names>DE</given-names></name><name><surname>Murphy</surname> <given-names>JE</given-names></name><name><surname>Craik</surname> <given-names>CS</given-names></name><name><surname>Hermiston</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e75141</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0075141</pub-id><pub-id pub-id-type="pmid">24073241</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obry</surname> <given-names>A</given-names></name><name><surname>Lequerré</surname> <given-names>T</given-names></name><name><surname>Hardouin</surname> <given-names>J</given-names></name><name><surname>Boyer</surname> <given-names>O</given-names></name><name><surname>Fardellone</surname> <given-names>P</given-names></name><name><surname>Philippe</surname> <given-names>P</given-names></name><name><surname>Le Loët</surname> <given-names>X</given-names></name><name><surname>Cosette</surname> <given-names>P</given-names></name><name><surname>Vittecoq</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e115800</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0115800</pub-id><pub-id pub-id-type="pmid">25546405</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottesen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>Induction of biological activity by limited proteolysis</article-title><source>Annual Review of Biochemistry</source><volume>36</volume><fpage>55</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.36.070167.000415</pub-id><pub-id pub-id-type="pmid">18257715</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paaby</surname> <given-names>AB</given-names></name><name><surname>Rockman</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The many faces of pleiotropy</article-title><source>Trends in Genetics</source><volume>29</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2012.10.010</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>BS</given-names></name><name><surname>Song</surname> <given-names>DH</given-names></name><name><surname>Kim</surname> <given-names>HM</given-names></name><name><surname>Choi</surname> <given-names>BS</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>JO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex</article-title><source>Nature</source><volume>458</volume><fpage>1191</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1038/nature07830</pub-id><pub-id pub-id-type="pmid">19252480</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavličev</surname> <given-names>M</given-names></name><name><surname>Cheverud</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Constraints evolve: context dependency of gene effects allows evolution of pleiotropy</article-title><source>Annual Review of Ecology, Evolution, and Systematics</source><volume>46</volume><fpage>413</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1146/annurev-ecolsys-120213-091721</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Shan</surname> <given-names>Z</given-names></name><name><surname>Teng</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Myeloid related proteins are up-regulated in autoimmune thyroid diseases and activate toll-like receptor 4 and pro-inflammatory cytokines in vitro</article-title><source>International Immunopharmacology</source><volume>59</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.04.009</pub-id><pub-id pub-id-type="pmid">29656212</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poltorak</surname> <given-names>A</given-names></name><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Smirnova</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>MY</given-names></name><name><surname>Van Huffel</surname> <given-names>C</given-names></name><name><surname>Du</surname> <given-names>X</given-names></name><name><surname>Birdwell</surname> <given-names>D</given-names></name><name><surname>Alejos</surname> <given-names>E</given-names></name><name><surname>Silva</surname> <given-names>M</given-names></name><name><surname>Galanos</surname> <given-names>C</given-names></name><name><surname>Freudenberg</surname> <given-names>M</given-names></name><name><surname>Ricciardi-Castagnoli</surname> <given-names>P</given-names></name><name><surname>Layton</surname> <given-names>B</given-names></name><name><surname>Beutler</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene</article-title><source>Science</source><volume>282</volume><fpage>2085</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1126/science.282.5396.2085</pub-id><pub-id pub-id-type="pmid">9851930</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postel</surname> <given-names>S</given-names></name><name><surname>Küfner</surname> <given-names>I</given-names></name><name><surname>Beuter</surname> <given-names>C</given-names></name><name><surname>Mazzotta</surname> <given-names>S</given-names></name><name><surname>Schwedt</surname> <given-names>A</given-names></name><name><surname>Borlotti</surname> <given-names>A</given-names></name><name><surname>Halter</surname> <given-names>T</given-names></name><name><surname>Kemmerling</surname> <given-names>B</given-names></name><name><surname>Nürnberger</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The multifunctional leucine-rich repeat receptor kinase BAK1 is implicated in Arabidopsis development and immunity</article-title><source>European Journal of Cell Biology</source><volume>89</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2009.11.001</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname> <given-names>LR</given-names></name><name><surname>Whyte</surname> <given-names>MK</given-names></name><name><surname>Sabroe</surname> <given-names>I</given-names></name><name><surname>Parker</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The role of TLRs in neutrophil activation</article-title><source>Current Opinion in Pharmacology</source><volume>11</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2011.06.007</pub-id><pub-id pub-id-type="pmid">21741310</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname> <given-names>M</given-names></name><name><surname>He</surname> <given-names>Z</given-names></name><name><surname>Källberg</surname> <given-names>E</given-names></name><name><surname>Ivars</surname> <given-names>F</given-names></name><name><surname>Leanderson</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human S100A9 protein is stabilized by inflammatory stimuli via the formation of proteolytically-resistant homodimers</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e61832</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061832</pub-id><pub-id pub-id-type="pmid">23626736</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubartelli</surname> <given-names>A</given-names></name><name><surname>Lotze</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox</article-title><source>Trends in Immunology</source><volume>28</volume><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.08.004</pub-id><pub-id pub-id-type="pmid">17845865</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Säemann</surname> <given-names>MD</given-names></name><name><surname>Haidinger</surname> <given-names>M</given-names></name><name><surname>Hecking</surname> <given-names>M</given-names></name><name><surname>Hörl</surname> <given-names>WH</given-names></name><name><surname>Weichhart</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The multifunctional role of mTOR in innate immunity: implications for transplant immunity</article-title><source>American Journal of Transplantation</source><volume>9</volume><fpage>2655</fpage><lpage>2661</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02832.x</pub-id><pub-id pub-id-type="pmid">19788500</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname> <given-names>I</given-names></name><name><surname>Malone</surname> <given-names>PS</given-names></name><name><surname>Mihaimeed</surname> <given-names>F</given-names></name><name><surname>Jones</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A review of the S100 proteins in Cancer</article-title><source>European Journal of Surgical Oncology</source><volume>34</volume><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2007.04.009</pub-id><pub-id pub-id-type="pmid">17566693</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiopu</surname> <given-names>A</given-names></name><name><surname>Cotoi</surname> <given-names>OS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>S100A8 and S100A9: damps at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease</article-title><source>Mediators of Inflammation</source><volume>2013</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2013/828354</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabani</surname> <given-names>F</given-names></name><name><surname>Farasat</surname> <given-names>A</given-names></name><name><surname>Mahdavi</surname> <given-names>M</given-names></name><name><surname>Gheibi</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Calprotectin (S100A8/S100A9): a key protein between inflammation and Cancer</article-title><source>Inflammation Research</source><volume>67</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1007/s00011-018-1173-4</pub-id><pub-id pub-id-type="pmid">30083975</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname> <given-names>CE</given-names></name><name><surname>Goyette</surname> <given-names>J</given-names></name><name><surname>Utter</surname> <given-names>V</given-names></name><name><surname>Rahimi</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Geczy</surname> <given-names>CL</given-names></name><name><surname>Halliday</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease</article-title><source>Neurobiology of Aging</source><volume>27</volume><fpage>1554</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.033</pub-id><pub-id pub-id-type="pmid">16253391</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>V</given-names></name><name><surname>Yeoh</surname> <given-names>BS</given-names></name><name><surname>Chassaing</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Saha</surname> <given-names>P</given-names></name><name><surname>Xiao</surname> <given-names>X</given-names></name><name><surname>Awasthi</surname> <given-names>D</given-names></name><name><surname>Shashidharamurthy</surname> <given-names>R</given-names></name><name><surname>Dikshit</surname> <given-names>M</given-names></name><name><surname>Gewirtz</surname> <given-names>A</given-names></name><name><surname>Vijay-Kumar</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Microbiota-inducible innate immune, siderophore binding protein lipocalin 2 is critical for intestinal homeostasis</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>2</volume><fpage>482</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2016.03.007</pub-id><pub-id pub-id-type="pmid">27458605</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapels</surname> <given-names>DA</given-names></name><name><surname>Geisbrecht</surname> <given-names>BV</given-names></name><name><surname>Rooijakkers</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutrophil serine proteases in antibacterial defense</article-title><source>Current Opinion in Microbiology</source><volume>23</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2014.11.002</pub-id><pub-id pub-id-type="pmid">25461571</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stearns</surname> <given-names>FW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>One hundred years of pleiotropy: a retrospective</article-title><source>Genetics</source><volume>186</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1534/genetics.110.122549</pub-id><pub-id pub-id-type="pmid">21062962</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streicher</surname> <given-names>WW</given-names></name><name><surname>Lopez</surname> <given-names>MM</given-names></name><name><surname>Makhatadze</surname> <given-names>GI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Modulation of quaternary structure of S100 proteins by calcium ions</article-title><source>Biophysical Chemistry</source><volume>151</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.bpc.2010.06.003</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stríz</surname> <given-names>I</given-names></name><name><surname>Trebichavský</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Calprotectin – a Pleiotropic Molecule in Acute and Chronic Inflammation</article-title><source>Physiological Research</source><volume>53</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">15209531</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname> <given-names>SY</given-names></name><name><surname>Segovia</surname> <given-names>JA</given-names></name><name><surname>Chang</surname> <given-names>TH</given-names></name><name><surname>Morris</surname> <given-names>IR</given-names></name><name><surname>Berton</surname> <given-names>MT</given-names></name><name><surname>Tessier</surname> <given-names>PA</given-names></name><name><surname>Tardif</surname> <given-names>MR</given-names></name><name><surname>Cesaro</surname> <given-names>A</given-names></name><name><surname>Bose</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1003848</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003848</pub-id><pub-id pub-id-type="pmid">24391503</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Tenbrock</surname> <given-names>K</given-names></name><name><surname>Ludwig</surname> <given-names>S</given-names></name><name><surname>Leukert</surname> <given-names>N</given-names></name><name><surname>Ehrhardt</surname> <given-names>C</given-names></name><name><surname>van Zoelen</surname> <given-names>MA</given-names></name><name><surname>Nacken</surname> <given-names>W</given-names></name><name><surname>Foell</surname> <given-names>D</given-names></name><name><surname>van der Poll</surname> <given-names>T</given-names></name><name><surname>Sorg</surname> <given-names>C</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1042</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/nm1638</pub-id><pub-id pub-id-type="pmid">17767165</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Gharibyan</surname> <given-names>AL</given-names></name><name><surname>Morozova-Roche</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes</article-title><source>International Journal of Molecular Sciences</source><volume>13</volume><fpage>2893</fpage><lpage>2917</lpage><pub-id pub-id-type="doi">10.3390/ijms13032893</pub-id><pub-id pub-id-type="pmid">22489132</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Eisenblätter</surname> <given-names>M</given-names></name><name><surname>Völler</surname> <given-names>T</given-names></name><name><surname>Zenker</surname> <given-names>S</given-names></name><name><surname>Hermann</surname> <given-names>S</given-names></name><name><surname>van Lent</surname> <given-names>P</given-names></name><name><surname>Faust</surname> <given-names>A</given-names></name><name><surname>Geyer</surname> <given-names>C</given-names></name><name><surname>Petersen</surname> <given-names>B</given-names></name><name><surname>Roebrock</surname> <given-names>K</given-names></name><name><surname>Schäfers</surname> <given-names>M</given-names></name><name><surname>Bremer</surname> <given-names>C</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4593</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5593</pub-id><pub-id pub-id-type="pmid">25098555</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname> <given-names>T</given-names></name><name><surname>Stratis</surname> <given-names>A</given-names></name><name><surname>Wixler</surname> <given-names>V</given-names></name><name><surname>Völler</surname> <given-names>T</given-names></name><name><surname>Thurainayagam</surname> <given-names>S</given-names></name><name><surname>Jorch</surname> <given-names>SK</given-names></name><name><surname>Zenker</surname> <given-names>S</given-names></name><name><surname>Dreiling</surname> <given-names>A</given-names></name><name><surname>Chakraborty</surname> <given-names>D</given-names></name><name><surname>Fröhling</surname> <given-names>M</given-names></name><name><surname>Paruzel</surname> <given-names>P</given-names></name><name><surname>Wehmeyer</surname> <given-names>C</given-names></name><name><surname>Hermann</surname> <given-names>S</given-names></name><name><surname>Papantonopoulou</surname> <given-names>O</given-names></name><name><surname>Geyer</surname> <given-names>C</given-names></name><name><surname>Loser</surname> <given-names>K</given-names></name><name><surname>Schäfers</surname> <given-names>M</given-names></name><name><surname>Ludwig</surname> <given-names>S</given-names></name><name><surname>Stoll</surname> <given-names>M</given-names></name><name><surname>Leanderson</surname> <given-names>T</given-names></name><name><surname>Schultze</surname> <given-names>JL</given-names></name><name><surname>König</surname> <given-names>S</given-names></name><name><surname>Pap</surname> <given-names>T</given-names></name><name><surname>Roth</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation</article-title><source>Journal of Clinical Investigation</source><volume>128</volume><fpage>1852</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1172/JCI89867</pub-id><pub-id pub-id-type="pmid">29611822</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname> <given-names>LC</given-names></name><name><surname>Donor</surname> <given-names>MT</given-names></name><name><surname>Prell</surname> <given-names>JS</given-names></name><name><surname>Harms</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multiple evolutionary origins of ubiquitous Cu2+ and Zn2+ binding in the S100 protein family</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0164740</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0164740</pub-id><pub-id pub-id-type="pmid">27764152</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Nei</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A new method of inference of ancestral nucleotide and amino acid sequences</article-title><source>Genetics</source><volume>141</volume><fpage>1641</fpage><lpage>1650</lpage><pub-id pub-id-type="pmid">8601501</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PAML 4: phylogenetic analysis by maximum likelihood</article-title><source>Molecular Biology and Evolution</source><volume>24</volume><fpage>1586</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1093/molbev/msm088</pub-id><pub-id pub-id-type="pmid">17483113</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54100.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Laub</surname><given-names>Michael T</given-names></name><role>Reviewing Editor</role><aff><institution>Massachusetts Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper uses careful ancestral reconstruction work to provide a compelling case for how a single mutation in the S100A9 innate immunity protein produced its pro-inflammatory activity while also increasing proteolytic susceptibility, with the antimicrobial activity evolving independently. The results provide a clear example of how pleiotropy can be 'positive'. There are still relatively few studies in which such careful reconstruction work has been done so the work should be regarded as important and as a significant advance by a broad audience.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Evolution of multifunctionality through a pleiotropic substitution in the innate immune protein S100A9&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wendy Garrett as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. <italic>eLife</italic></p><p>Summary:</p><p>The reviewers each appreciated this well-written manuscript in which Harman et al. dissect the functional evolution of the S100A9 innate immune protein. Through careful ancestral reconstruction work, the authors provide a compelling case for how a single mutation produced the pro-inflammatory activity while also increasing proteolytic susceptibility, with the antimicrobial activity apparently independent. Together, the results provide a clear example of how pleiotropy can be 'positive'. There are still relatively few studies in which such careful reconstruction work has been done so the work was regarded as important and a significant advance.</p><p>Essential revisions:</p><p>1) The biggest claim for the study's impact relates to adaptive evolution under the potential constraint of multifunctionality. However, it wasn't clear to me how surprising the finding is given the location of the dimer interface relative to the M63F point mutation. Would there have to be a substantial allosteric effect to disrupt the interface? At least from the homodimeric A9 interaction illustrated in Figure 5A, it appears somewhat distant. Is that true of the antimicrobial heterodimer and/or its ability to coordinate and sequester metals? Related to this issue is the question of the functional impact of the pleiotropic M63F mutation. The notion of a proteolytic timer to control inflammatory signaling is intriguing, but is there any evidence that it has such a function or is it simply a coincidence with selection exclusive for TLR4 activation?</p><p>2) In general, the authors did a nice job of weighing evidence and balancing possible ambiguities in their results and different potential evolutionary scenarios that might break parsimony. However, it would be useful to have a better sense of how much uncertainty exists in the ancestral protein reconstructions (described in some places but not others). How many total substitutions are made compared to the modern variants and some help interpreting posterior probability values and the range of evolutionary space missing in the ancestral and alternate ancestral pairs.</p><p>3) The characterization of how additional point mutants influence S100A9 function could help to strengthen the argument that the proteolytic sensitivity and pro-inflammatory activities are coupled, but are relatively independent from the mutations influencing hA8/hA9 complex formation and antibacterial activity. However, this would add substantially more work, and it is unclear if it would dramatically reshape the main claims of the paper. Please comment. At a minimum, the authors should address in their responses and revision how much was already known, or not, about the functional coupling of the proteolytic and pro-inflammatory activities.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54100.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The biggest claim for the study's impact relates to adaptive evolution under the potential constraint of multifunctionality. However, it wasn't clear to me how surprising the finding is given the location of the dimer interface relative to the M63F point mutation. Would there have to be a substantial allosteric effect to disrupt the interface? At least from the homodimeric A9 interaction illustrated in Figure 5A, it appears somewhat distant. Is that true of the antimicrobial heterodimer and/or its ability to coordinate and sequester metals? Related to this issue is the question of the functional impact of the pleiotropic M63F mutation. The notion of a proteolytic timer to control inflammatory signaling is intriguing, but is there any evidence that it has such a function or is it simply a coincidence with selection exclusive for TLR4 activation?</p></disp-quote><p>These are excellent points made by the reviewers that we have now expanded upon in the manuscript. We have addressed this question in two parts:</p><p>1a) Is it surprising that M63F doesn’t affect the A8/A9 complex despite its distance from the antimicrobial site and A8/A9 interface?</p><p>Given the location, the lack of effect is unsurprising. That said, the spatial separation of the sites – and the resulting lack of pleiotropy – is a result of our analysis, not a premise. We began this study wondering how multifunctionality could evolve given the possibility of pleiotropy.We did not know a priori which mutation(s) would be important for A9’s various functions, particularly since the interface through which A9 exerts proinflammatory activity is unknown. We identified the historical F63M substitution and showed that it affects both A9 proinflammatory activity and proteolytic resistance. Because position 63 is relatively far from the A8/A9 complex interface and metal sequestration site, it is unsurprising that mutating M63F has little effect on the A8/A9 complex. But we did not know where this mutation would be when we started the project.</p><p>We have altered the Results section where we describe this result to clarify this line of reasoning:</p><p>“A primary goal of this study was to understand the role of pleiotropy in the evolution of multifunctionality. […] These findings suggest that this single amino acid position had important effects on the evolution of A9 activation of TLR4 and loss of proteolytic resistance without significantly impacting A8/A9 oligomeric state, proteolytic resistance, or antimicrobial activity.”</p><p>1b) What is the functional significance, if any, of A9 losing proteolytic resistance? Is it simply coincident with A9 evolving proinflammatory activity?</p><p>To address this question, we have done a new set of experiments and made three modifications to the text:</p><p>To support the idea that A9 can be plausibly regulated by proteases found at sites of inflammation, we performed an experiment in which we tested both A9 and A9 M63F for proteolytic resistance against two common neutrophil proteases. These results are described in the Results:</p><p>“To relate these findings to proteases that A9 might encounter at sites of inflammation, we also measured the proteolytic resistance of human A9 and human A9 M63F against two neutrophil-specific proteases – cathepsin G and neutrophil elastase (Figure 4—figure supplement 2). […] We found that M63F decreased the rate of human A9 degradation in the presence of cathepsin G and neutrophil elastase in vitro by approximately one order of magnitude, matching our results using proteinase K (Figure 4—figure supplement 1).”</p><p>Second, we altered the Introduction to clarify what is known at this time:</p><p>“An additional layer of A9 immune function is that A9 and A8/A9 are thought to be regulated in the extracellular milieu by proteases. […] There is no obvious way to selectively increase the proteolytic resistance of A9 and test its effect on A9 activation of TLR4, making it difficult to understand the relationship, if any, between these two functions.”</p><p>Third, we now explicitly articulate three possible reasons for A9 loss of proteolytic resistance in the Discussion. The newly reorganized section reads:</p><p>“Why did A9s lose proteolytic resistance?</p><p>While proteolysis is not required for A9 activation of TLR4, it remains unclear why A9s lost proteolytic resistance. […] As A9s activate TLR4 in the protease-rich extracellular space, the functional result of A9 loss of proteolytic resistance is that A9s evolved a proteolytic “timer” concomitantly with evolving proinflammatory activity, all without affecting A8/A9 function.”</p><disp-quote content-type="editor-comment"><p>2) In general, the authors did a nice job of weighing evidence and balancing possible ambiguities in their results and different potential evolutionary scenarios that might break parsimony. However, it would be useful to have a better sense of how much uncertainty exists in the ancestral protein reconstructions (described in some places but not others). How many total substitutions are made compared to the modern variants and some help interpreting posterior probability values and the range of evolutionary space missing in the ancestral and alternate ancestral pairs.</p></disp-quote><p>We thank the reviewers for requesting these clarifications and have added the following to the Results section:</p><p>“AncA8 and ancA9 had average posterior probabilities of 0.88 and 0.83, with sequence similarities to human A8 and A9 of 66% and 64%, respectively (Figure 1—figure supplement 4). Average posterior probabilities in this range have been previously described as medium confidence reconstructions, with reconstructions characterized by others having average posterior probabilities as low as 0.7.”</p><p>We have also altered the text to explicitly state the number of sequence changes between the ML and AltAll reconstructions:</p><p>“AncA8/A9 and altancA8/A9 differ by 27 amino acids total (10 between ancA8 and altancA8 and 17 between ancA9 and altancA9 – Figure 1—figure supplement 4).”</p><p>And here:</p><p>“We used ASR to reconstruct the shared amniote ancestor of A9s, A8s, A12s, and MRP126s. […] We also constructed an alternate, “alt All” version of this ancestor (altancCG, S4), which differed from ancCG by 8 amino acids. The average posterior probability of ancCG was 0.86 (Figure 1—figure supplement 4).”</p><disp-quote content-type="editor-comment"><p>3) The characterization of how additional point mutants influence S100A9 function could help to strengthen the argument that the proteolytic sensitivity and pro-inflammatory activities are coupled, but are relatively independent from the mutations influencing hA8/hA9 complex formation and antibacterial activity. However, this would add substantially more work, and it is unclear if it would dramatically reshape the main claims of the paper. Please comment. At a minimum, the authors should address in their responses and revision how much was already known, or not, about the functional coupling of the proteolytic and pro-inflammatory activities.</p></disp-quote><p>These questions were a primary motivation for this work: to our knowledge, no previous study has characterized S100A9 mutations that alter both proteolytic resistance and proinflammatory activity. Previous work has shown A9 mutations that alter in vitro binding to TLR4 (Vogl et al., 2018); proteolytic fragments of A9 are sufficient to activate TLR4 (Vogl et al., 2018); proinflammatory stimuli stabilize A9 homodimers against proteolytic degradation (Riva et al., 2013); and mutating zinc-binding residues or removing the disordered C-terminal extension of A9 do not alter A9 activation of TLR4 (Loes et al. bioRxiv preprint). However, no studies to date have simultaneously examined mutations that affect both A9 proteolytic resistance and proinflammatory activity.</p><p>A challenge that we highlight in the Introduction is that there is no obvious way to selectively increase the proteolytic resistance of A9 to test its role in A9 proinflammatory activity. In this study we show that the M63F mutation both increases A9 proteolytic resistance and decreases proinflammatory activity, further suggesting a relationship between these two functions. We then showed that proteolysis is not required for A9 proinflammatory activity because 1) the A9 proteins do not get degraded in the proinflammatory assay, and 2) hA9 M63A, which is proteolytically susceptible, exhibits weaker proinflammatory activity than wildtype A9 (Figure 6).</p><p>To clarify previous work by others examining the relationship between proteolysis and A9 proinflammatory activity, we have altered the Introduction (see text changes in essential revision #1b). We have also altered the Discussion to clarify what we believe to be the functional relationship between A9 proteolysis and proinflammatory activity:</p><p>“While we cannot explicitly distinguish between each of these possibilities, the end result is that A9s lost proteolytic resistance from a resistant ancestor. As A9s activate TLR4 in the protease-rich extracellular space, the functional result A9 loss of proteolytic resistance is that A9s evolved a proteolytic “timer” concomitantly with evolving proinflammatory activity, all without affecting A8/A9 function.”</p></body></sub-article></article>